Johnson & Johnson (JNJ) 10-Q 28 Oct 19 2019 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 29, 2019	Oct. 22, 2019
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 29, 2019
Document Transition Report	false
Entity File Number	1-3215
Entity Registrant Name	Johnson & Johnson
Entity Incorporation, State or Country Code	NJ
Entity Tax Identification Number	22-1024240
Entity Address, Address Line One	One Johnson & Johnson Plaza
Entity Address, City or Town	New Brunswick
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08933
City Area Code	732
Local Phone Number	524-0400
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		2,631,872,399
Entity Central Index Key	0000200406
Current Fiscal Year End Date	--12-29
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false
Common Stock, Par Value $1.00
Entity Information [Line Items]
Title of 12(b) Security	Common Stock, Par Value $1.00
Trading Symbol	JNJ
Security Exchange Name	NYSE
4.75% Notes Due November 2019
Entity Information [Line Items]
Title of 12(b) Security	4.75% Notes Due November 2019
Trading Symbol	JNJ
Security Exchange Name	NYSE
0.250% Notes Due January 2022
Entity Information [Line Items]
Title of 12(b) Security	0.250% Notes Due January 2022
Trading Symbol	JNJ
Security Exchange Name	NYSE
0.650% Notes Due May 2024
Entity Information [Line Items]
Title of 12(b) Security	0.650% Notes Due May 2024
Trading Symbol	JNJ
Security Exchange Name	NYSE
5.50% Notes Due November 2024
Entity Information [Line Items]
Title of 12(b) Security	5.50% Notes Due November 2024
Trading Symbol	JNJ
Security Exchange Name	NYSE
1.150% Notes Due November 2028
Entity Information [Line Items]
Title of 12(b) Security	1.150% Notes Due November 2028
Trading Symbol	JNJ
Security Exchange Name	NYSE
1.650% Notes Due May 2035
Entity Information [Line Items]
Title of 12(b) Security	1.650% Notes Due May 2035
Trading Symbol	JNJ
Security Exchange Name	NYSE

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 29, 2019	Dec. 30, 2018
Current assets:
Cash and cash equivalents	$ 16,249	$ 18,107
Marketable securities	1,696	1,580
Accounts receivable, trade, less allowances for doubtful accounts $227 (2018, $248)	14,801	14,098
Inventories (Note 2)	9,173	8,599
Prepaid expenses and other	2,220	2,699
Assets held for sale (Note 10)	194	950
Total current assets	44,333	46,033
Property, plant and equipment at cost	42,625	41,851
Less: accumulated depreciation	(25,577)	(24,816)
Property, plant and equipment, net	17,048	17,035
Intangible assets, net (Note 3)	47,846	47,611
Goodwill (Note 3)	33,291	30,453
Deferred taxes on income	7,696	7,640
Other assets	5,307	4,182
Total assets	155,521	152,954
Current liabilities:
Loans and notes payable	2,299	2,796
Accounts payable	7,491	7,537
Accrued liabilities	9,004	7,601
Accrued rebates, returns and promotions	10,977	9,380
Accrued compensation and employee related obligations	2,886	3,098
Accrued taxes on income	2,505	818
Total current liabilities	35,162	31,230
Long-term debt (Note 4)	26,919	27,684
Deferred taxes on income	6,526	7,506
Employee related obligations	9,830	9,951
Long-term taxes payable	7,493	8,242
Other liabilities	11,381	8,589
Total liabilities	97,311	93,202
Commitments and Contingencies (Note 11)
Shareholders’ equity:
Common stock — par value $1.00 per share (authorized 4,320,000,000 shares; issued 3,119,843,000 shares)	3,120	3,120
Accumulated other comprehensive income (loss) (Note 7)	(15,533)	(15,222)
Retained earnings	109,242	106,216
Less: common stock held in treasury, at cost (488,882,000 and 457,519,000 shares)	38,619	34,362
Total shareholders’ equity	58,210	59,752
Total liabilities and shareholders' equity	$ 155,521	$ 152,954

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Sep. 29, 2019	Dec. 30, 2018
Current assets:
Allowances for doubtful accounts	$ 227	$ 248
Shareholders' equity:
Common stock, par value per share	$ 1	$ 1
Common stock, shares authorized	4,320,000,000	4,320,000,000
Common stock, shares issued	3,119,843,000	3,119,843,000
Treasury stock, shares	488,882,000	457,519,000

Consolidated Statements of Earn

Consolidated Statements of Earnings - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Income Statement [Abstract]
Sales to customers	$ 20,729	$ 20,348	$ 61,312	$ 61,187
Sales to customers percent to sales	100.00%	100.00%	100.00%	100.00%
Cost of products sold	$ 6,867	$ 6,589	$ 20,422	$ 20,130
Cost of products sold percent to sales	33.10%	32.40%	33.30%	32.90%
Gross profit	$ 13,862	$ 13,759	$ 40,890	$ 41,057
Gross profit percent to sales	66.90%	67.60%	66.70%	67.10%
Selling, marketing and administrative expenses	$ 5,374	$ 5,543	$ 16,139	$ 16,549
Selling marketing and administrative expenses percent to sales	26.00%	27.30%	26.30%	27.10%
Research and development expense	$ 2,599	$ 2,508	$ 8,123	$ 7,551
Research and development expense percent to sales	12.50%	12.30%	13.30%	12.30%
In-process research and development	$ 0	$ 1,126	$ 890	$ 1,126
In-process research and development percent to sales	0.00%	5.60%	1.40%	1.80%
Interest income	$ (89)	$ (175)	$ (276)	$ (415)
Interest income percent to sales	(0.40%)	(0.90%)	(0.50%)	(0.60%)
Interest expense, net of portion capitalized	$ 48	$ 243	$ 233	$ 755
Interest expense, net of portion capitalized percent to sales	0.20%	1.20%	0.40%	1.20%
Other (income) expense, net	$ 4,214	$ 3	$ 2,509	$ 427
Other (income) expense, net percent to sales	20.30%	0.00%	4.10%	0.70%
Restructuring (Note 12)	$ 69	$ 88	$ 162	$ 187
Restructuring charge percent to sales	0.40%	0.40%	0.30%	0.30%
Earnings before provision for taxes on income	$ 1,647	$ 4,423	$ 13,110	$ 14,877
Earnings before provision for taxes on income percent to sales	7.90%	21.70%	21.40%	24.30%
Provision for taxes on income	$ (106)	$ 489	$ 2,001	$ 2,622
Provision for (Benefit from) taxes on income (Note 5)	(0.60%)	2.40%	3.30%	4.30%
NET EARNINGS	$ 1,753	$ 3,934	$ 11,109	$ 12,255
Net earnings percent to sales	8.50%	19.30%	18.10%	20.00%
NET EARNINGS PER SHARE
Basic (per share)	$ 0.67	$ 1.47	$ 4.19	$ 4.57
Diluted (per share)	$ 0.66	$ 1.44	$ 4.13	$ 4.49
AVG. SHARES OUTSTANDING
Basic (shares)	2,635.2	2,683.2	2,649.5	2,682.6
Diluted (shares)	2,669.9	2,727.6	2,688.1	2,729.6

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Statement of Comprehensive Income [Abstract]
Net earnings	$ 1,753	$ 3,934	$ 11,109	$ 12,255
Other comprehensive income (loss), net of tax
Foreign currency translation	(667)	(151)	(575)	(1,718)
Securities:
Unrealized holding gain (loss) arising during period	0	0	1	0
Reclassifications to earnings	0	(1)	0	(1)
Net change	0	(1)	1	(1)
Employee benefit plans:
Prior service cost amortization during period	(6)	(6)	(18)	(17)
Gain (loss) amortization during period	142	192	460	574
Net change	136	186	442	557
Derivatives & hedges:
Unrealized gain (loss) arising during period	1,922	262	1,706	37
Reclassifications to earnings	(1,955)	(166)	(1,885)	(91)
Net change	(33)	96	(179)	(54)
Other comprehensive income (loss)	(564)	130	(311)	(1,216)
Comprehensive income	1,189	4,064	10,798	11,039
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax	(94)	104	(50)	(79)
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax	34	52	69	155
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax	$ (9)	$ 26	$ (48)	$ (14)

Consolidated Statements of Equi

Consolidated Statements of Equity - USD ($) $ in Millions	Total	Retained Earnings	Accumulated Other Comprehensive Income	Common Stock Issued Amount	Treasury Stock Amount
Beginning Balance at Dec. 31, 2017	$ 60,160	$ 101,793	$ (13,199)	$ 3,120	$ (31,554)
Cumulative Adjustment to retained earnings	1,264	1,496	(232)
Net earnings	12,255	12,255
Cash dividends paid	(7,083)	(7,083)
Employee compensation and stock option plans	1,320	(830)			2,150
Repurchase of common stock	(2,060)				(2,060)
Other	(14)	(14)
Other comprehensive income (loss), net of tax	(1,216)		(1,216)
Ending Balance at Sep. 30, 2018	64,626	107,617	(14,647)	3,120	(31,464)
Beginning Balance at Jul. 01, 2018	62,889	106,123	(14,777)	3,120	(31,577)
Cumulative Adjustment to retained earnings	0
Net earnings	3,934	3,934
Cash dividends paid	(2,415)	(2,415)
Employee compensation and stock option plans	560	(24)			584
Repurchase of common stock	(471)				(471)
Other	(1)	(1)
Other comprehensive income (loss), net of tax	130		130
Ending Balance at Sep. 30, 2018	64,626	107,617	(14,647)	3,120	(31,464)
Beginning Balance at Dec. 30, 2018	59,752	106,216	(15,222)	3,120	(34,362)
Net earnings	11,109	11,109
Cash dividends paid	(7,417)	(7,417)
Employee compensation and stock option plans	1,397	(666)			2,063
Repurchase of common stock	(6,320)				(6,320)
Other comprehensive income (loss), net of tax	(311)		(311)
Ending Balance at Sep. 29, 2019	58,210	109,242	(15,533)	3,120	(38,619)
Beginning Balance at Jun. 30, 2019	60,785	109,809	(14,969)	3,120	(37,175)
Net earnings	1,753	1,753
Cash dividends paid	(2,499)	(2,499)
Employee compensation and stock option plans	363	179			184
Repurchase of common stock	(1,628)				(1,628)
Other comprehensive income (loss), net of tax	(564)		(564)
Ending Balance at Sep. 29, 2019	$ 58,210	$ 109,242	$ (15,533)	$ 3,120	$ (38,619)

Consolidated Statements of Eq_2

Consolidated Statements of Equity (Parenthetical) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Statement of Stockholders' Equity [Abstract]
Cash dividends paid (in dollars per share)	$ 0.95	$ 0.90	$ 2.80	$ 2.64

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net earnings	$ 11,109	$ 12,255
Adjustments to reconcile net earnings to cash flows from operating activities:
Depreciation and amortization of property and intangibles	5,193	5,194
Stock based compensation	817	822
Asset write-downs	1,019	1,226
Net gain on sale of assets/businesses	(2,125)	(443)
Deferred tax provision	(2,126)	53
Accounts receivable allowances	(15)	(3)
Changes in assets and liabilities, net of effects from acquisitions and divestitures:
Increase in accounts receivable	(665)	(1,040)
Increase in inventories	(424)	(777)
Increase in accounts payable and accrued liabilities	2,273	731
Increase in other current and non-current assets	(81)	(904)
Increase / (Decrease) in other current and non-current liabilities	2,043	(1,157)
NET CASH FLOWS FROM OPERATING ACTIVITIES	17,018	15,957
CASH FLOWS FROM INVESTING ACTIVITIES
Additions to property, plant and equipment	(2,238)	(2,352)
Proceeds from the disposal of assets/businesses, net	3,103	895
Acquisitions, net of cash acquired	(5,562)	(897)
Purchases of investments	(2,684)	(4,155)
Sales of investments	2,459	1,162
Other	72	(48)
NET CASH USED BY INVESTING ACTIVITIES	(4,850)	(5,395)
CASH FLOWS FROM FINANCING ACTIVITIES
Dividends to shareholders	(7,417)	(7,083)
Repurchase of common stock	(6,320)	(2,060)
Proceeds from short-term debt	148	40
Retirement of short-term debt	(87)	(2,365)
Proceeds from long-term debt, net of issuance costs	1	6
Retirement of long-term debt	(1,008)	(910)
Proceeds from the exercise of stock options/employee withholding tax on stock awards, net	580	480
Other	160	(229)
NET CASH USED BY FINANCING ACTIVITIES	(13,943)	(12,121)
Effect of exchange rate changes on cash and cash equivalents	(83)	(209)
Decrease in cash and cash equivalents	(1,858)	(1,768)
Cash and Cash equivalents, beginning of period	18,107	17,824
Cash and Cash equivalents, end of period	16,249	16,056
Acquisitions
Fair value of assets acquired	6,861	1,046
Fair value of liabilities assumed and noncontrolling interests	(1,299)	(149)
Net cash paid for acquisitions	$ 5,562	$ 897

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 29, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	The accompanying unaudited interim consolidated financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of Johnson & Johnson and its subsidiaries (the Company) and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 30, 2018 . The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures. New Accounting Standards Recently Adopted Accounting Standards ASU 2016-02 : Leases The Company adopted this standard as of the beginning of fiscal year 2019, on a prospective basis. This update requires the recognition of lease assets and lease liabilities on the balance sheet for all lease obligations and disclosing key information about leasing arrangements. This update requires the recognition of lease assets and lease liabilities by lessees for arrangements that are classified as operating leases. The Company’s operating leases resulted in the recognition of additional assets and the corresponding liabilities on its Consolidated Balance Sheet, however it did not have a material impact on the consolidated financial statements. The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in Other assets, Accrued liabilities, and Other liabilities on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet. ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. The Company primarily has operating leases for space, vehicles, manufacturing equipment, and data processing equipment. Leases have remaining lease terms ranging from 1 year to 55 years , some of which could include options to extend the leases when they are reasonably certain. As noted in the Company’s 2018 10-K, the approximate minimum rental payments required under operating leases that had initial or remaining non-cancelable lease terms in excess of one year at December 30, 2018 were: (Dollars in Millions) 2019 2020 2021 2022 2023 After 2023 Total $223 188 154 116 76 139 896 Commitments under finance leases are not significant. Maturity of Lease Liabilities related to Operating Lease The minimum rental payments required under operating leases that have initial or remaining non-cancellable lease terms in excess of one year as of September 29, 2019 are: (Dollars in Millions) Operating Leases 2019 (for the remainder of fiscal 2019) $ 82 2020 274 2021 218 2022 160 2023 106 After 2023 241 Total lease payments 1,081 Less: Interest 89 Present Value of lease liabilities $ 992 The Weighted Average Remaining Lease Term and discount rate: Operating leases 5.8 years Weighted Average Discount Rate 3% For the fiscal third quarter and fiscal nine months ended September 29, 2019, the operating lease costs were $103 million and $227 million , respectively. Cash paid for amounts included in the measurement of lease liabilities were $86 million and $233 million for the fiscal third quarter and fiscal nine months of 2019, respectively. Other supplemental information related to these leases are as follows: Supplemental balance sheet information (for the fiscal third quarter ended September 29, 2019) : (Dollars in Millions) Non-current operating lease right-of-use assets $ 963 Current operating lease liabilities 266 Non-current Operating lease liabilities 726 Total operating lease liabilities $ 992 ASU 2018-02 : Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income This update allows a Company to elect to reclassify stranded tax effects resulting from the Tax Cuts and Job Act enacted in December 2017 from accumulated other comprehensive income to retained earnings. The Company has elected not to reclassify the income tax effects of this standard and therefore this standard will not impact the Company's consolidated financial statements. ASU 2018-16 : Derivatives and Hedging (Topic ASC 815) This update adds the Overnight Index Swap (OIS) rate based on the Secured Overnight Financing Rate (SOFR) as an eligible benchmark interest rate permitted in the application of hedge accounting. The guidance was effective for the Company as of the fiscal fourth quarter of 2018, due to the previous adoption of ASU 2017-12. The impact of the adoption of this guidance did not have a material impact on the Company’s consolidated financial statements and related disclosures. The standard may have an impact in the future as the market for SOFR derivatives develops over time and if SOFR is used to hedge the Company’s financial instruments. Recently Issued Accounting Standards Not Adopted as of September 29, 2019 ASU 2018-18 : Collaborative Arrangements This update clarifies the interaction between ASC 808, Collaborative Arrangements and ASC 606, Revenue from Contracts with Customers. The update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer. In addition, the update precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue if the counterparty is not a customer for that transaction. This update will be effective for the Company for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. ASU 2018-18 should be applied retrospectively to the date of initial application of ASC 606 and early adoption is permitted. The adoption of this standard will not have a material impact on the Company’s consolidated financial statements. ASU 2016-13 : Financial Instruments - Credit Losses This update introduces the current expected credit loss (CECL) model, which will require an entity to measure credit losses for certain financial instruments and financial assets, including trade receivables. Under this update, on initial recognition and at each reporting period, an entity will be required to recognize an allowance that reflects the entity’s current estimate of credit losses expected to be incurred over the life of the financial instrument. This update will be effective for the Company for fiscal years beginning after December 15, 2019 and interim periods within those fiscal years. Early adoption is permitted. The adoption of this standard will not have a material impact on the Company’s consolidated financial statements.

Inventories

Inventories	9 Months Ended
	Sep. 29, 2019
Inventory Disclosure [Abstract]
Inventories	INVENTORIES (Dollars in Millions) September 29, 2019 December 30, 2018 Raw materials and supplies $ 1,094 1,114 Goods in process 2,000 2,109 Finished goods 6,079 5,376 Total inventories (1) $ 9,173 8,599 (1) The balance as of September 29, 2019, does not include the assets held for sale related to the strategic collaboration with Jabil Inc. of approximately $0.2 billion . The balance as of December 30, 2018, does not include the assets held for sale related to the divestiture of the Advanced Sterilization Products (ASP) business of approximately $0.2 billion and $0.3 billion

Intangible Assets and Goodwill

Intangible Assets and Goodwill	9 Months Ended
	Sep. 29, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	INTANGIBLE ASSETS AND GOODWILL Intangible assets that have finite useful lives are amortized over their estimated useful lives. The latest annual impairment assessment of goodwill and indefinite lived intangible assets was completed in the fiscal fourth quarter of 2018 . Future impairment tests for goodwill and indefinite lived intangible assets will be performed annually in the fiscal fourth quarter, or sooner, if warranted. (Dollars in Millions) September 29, 2019 December 30, 2018 Intangible assets with definite lives: Patents and trademarks — gross $ 36,114 35,194 Less accumulated amortization 12,158 9,784 Patents and trademarks — net 23,956 25,410 Customer relationships and other intangibles — gross 21,845 21,334 Less accumulated amortization 9,120 8,323 Customer relationships and other intangibles — net 12,725 13,011 Intangible assets with indefinite lives: Trademarks 6,875 6,937 Purchased in-process research and development (1) 4,290 2,253 Total intangible assets with indefinite lives 11,165 9,190 Total intangible assets — net $ 47,846 47,611 (1) In the fiscal first quarter of 2019, the Company recorded an IPR&D impairment charge of $0.9 billion for the remaining intangible asset value related to the development program of AL-8176, an investigational drug for the treatment of Respiratory Syncytial Virus (RSV) and human metapneumovirus (hMPV) acquired with the 2014 acquisition of Alios Biopharma Inc. The impairment charge was based on additional information, including clinical data, which became available and led to the Company's decision to abandon the development of AL-8176. A partial impairment charge of $0.8 billion was previously recorded in the fiscal third quarter of 2018 related to the development program of AL-8176. In the fiscal second quarter of 2019, the Company completed the acquisition of Auris Health, Inc. and recorded an in-process research and development intangible asset of $2.9 billion . Goodwill as of September 29, 2019 was allocated by segment of business as follows: (Dollars in Millions) Consumer Pharm Med Devices Total Goodwill at December 30, 2018 $ 8,670 9,063 12,720 30,453 Goodwill, related to acquisitions 1,191 — 2,018 3,209 Currency translation/Other (266 ) (86 ) (19 ) (371 ) Goodwill at September 29, 2019 $ 9,595 8,977 14,719 33,291 The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable intangible assets included in cost of products sold was $1.1 billion for each of the fiscal third quarters ended September 29, 2019 and September 30, 2018 . The amortization expense of amortizable intangible assets included in cost of products sold was $3.3 billion for each of the fiscal nine months ended September 29, 2019 and September 30, 2018 . The estimated amortization expense for the five succeeding years approximates $4.4 billion , before tax, per year. Intangible asset write-downs are included in Other (income) expense, net. See Note 10 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 29, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany product and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges. Additionally, the Company uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges, and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. The Company early adopted ASU 2017-12: Targeted Improvements to Accounting for Hedge Activities effective as of the beginning of fiscal second quarter of 2018. The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of September 29, 2019 , the total amount of collateral received under the credit support agreements (CSA) amounted to $68 million , net. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of September 29, 2019 , the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $47.3 billion , $18.8 billion and $0.5 billion , respectively. As of December 30, 2018 , the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $41.1 billion , $7.3 billion and $0.5 billion , respectively. All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction. The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings. Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings and are then reclassified to earnings in the same account as the hedged transaction. Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted for through the currency translation account within accumulated other comprehensive income. The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued. The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. As of September 29, 2019 , the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $374 million after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note 7. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months , excluding interest rate contracts, net investment hedges and equity collar contracts. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative. The following table is a summary of the activity related to derivatives and hedges for the fiscal third quarters ended in 2019 and 2018 : September 29, 2019 September 30, 2018 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $ — — — (3 ) — — — — (7 ) — Derivatives designated as hedging instruments — — — 3 — — — — 7 — Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 39 — — — — 25 — Amount of gain or (loss) recognized in AOCI — — — 39 — — — — 25 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income (8 ) (77 ) 1,911 — 1 4 97 10 — (3 ) Amount of gain or (loss) recognized in AOCI (23 ) (197 ) 1,939 — 5 15 192 (4 ) — (1 ) Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 89 — — — 34 — Amount of gain or (loss) recognized in AOCI $ — — — 159 — — — — 35 — The following table is a summary of the activity related to derivatives and hedges for the fiscal nine months ended in 2019 and 2018 : September 29, 2019 September 30, 2018 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $ — — — (2 ) — — — — 3 — Derivatives designated as hedging instruments — — — 2 — — — — (3 ) — Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 117 — — — — 27 — Amount of gain or (loss) recognized in AOCI — — — 117 — — — — 27 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income (43 ) (213 ) 1,808 — 9 50 175 (242 ) — (24 ) Amount of gain or (loss) recognized in AOCI (29 ) (543 ) 1,847 — 15 (3 ) 138 (220 ) — (16 ) Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 207 — — — — 106 — Amount of gain or (loss) recognized in AOCI $ — — — 299 — — — — 111 — As of September 29, 2019 , and December 30, 2018 , the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges: Line item in the Consolidated Balance Sheet in which the hedged item is included Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability (Dollars in Millions) September 29, 2019 December 30, 2018 September 29, 2019 December 30, 2018 Current Portion of Long-term Debt $ 502 494 (2 ) 5 Long-term Debt — — — — The following table is the effect of derivatives not designated as hedging instrument for the fiscal third quarter and fiscal nine months ended in 2019 and 2018: Gain/(Loss) Recognized In Income on Derivative Gain/(Loss) Recognized In Income on Derivative (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Fiscal Third Quarter Ended Fiscal Nine Months Ended Derivatives Not Designated as Hedging Instruments September 29, 2019 September 30, 2018 September 29, 2019 September 30, 2018 Foreign Exchange Contracts Other (income) expense $ (13 ) 49 (101 ) (23 ) The following table is the effect of net investment hedges for the fiscal third quarters ended in 2019 and 2018 Gain/(Loss) Recognized In Accumulated OCI Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From Accumulated OCI Into Income (Dollars in Millions) September 29, 2019 September 30, 2018 September 29, 2019 September 30, 2018 Debt $ 162 (50 ) Other (income) expense — — Cross Currency interest rate swaps $ 152 (75 ) Other (income) expense — — The following table is the effect of net investment hedges for the fiscal nine months ended in 2019 and 2018 : Gain/(Loss) Recognized In Accumulated OCI Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From Accumulated OCI Into Income (Dollars in Millions) September 29, 2019 September 30, 2018 September 29, 2019 September 30, 2018 Debt $ 176 106 Other (income) expense — — Cross Currency interest rate swaps $ 465 (37 ) Other (income) expense — — The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company has elected to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. The following table is a summary of the activity related to equity investments: (Dollars in Millions) December 30, 2018 September 29, 2019 Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 511 201 151 863 863 Equity Investments without readily determinable value $ 681 (28 ) 46 699 699 (1) Recorded in Other Income/Expense (2) Other includes impact of currency For equity investments without readily determinable market values, $29 million of the decrease in the fair value reflected in net income were the result of impairments. There was a $1 million increase in the fair value reflected in net income due to changes in observable prices. Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. In accordance with ASC 820, a three-level hierarchy was established to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level 1 inputs having the highest priority and Level 3 inputs having the lowest. The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S. Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company’s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level 1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations. The following three levels of inputs are used to measure fair value: Level 1 — Quoted prices in active markets for identical assets and liabilities. Level 2 — Significant other observable inputs. Level 3 — Significant unobservable inputs. The Company’s significant financial assets and liabilities measured at fair value as of September 29, 2019 and December 30, 2018 were as follows: September 29, 2019 December 30, 2018 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 498 — 498 501 Interest rate contracts (2)(4) — 681 — 681 161 Total — 1,179 — 1,179 662 Liabilities: Forward foreign exchange contracts — 635 — 635 548 Interest rate contracts (3)(4) — 410 — 410 292 Total — 1,045 — 1,045 840 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts — 32 — 32 32 Liabilities: Forward foreign exchange contracts — 38 — 38 32 Other Investments: Equity investments (5) 863 — — 863 511 Debt securities (6) $ — 4,327 — 4,327 9,734 Other Liabilities Contingent consideration (7) 1,596 1,596 335 Gross to Net Derivative Reconciliation September 29, 2019 December 30, 2018 (Dollars in Millions) Total Gross Assets $ 1,211 694 Credit Support Agreement (CSA) (1,013 ) (423 ) Total Net Asset 198 271 Total Gross Liabilities 1,083 872 Credit Support Agreement (CSA) (945 ) (605 ) Total Net Liabilities $ 138 267 Summarized information about changes in liabilities for contingent consideration is as follows: Nine months ended September 29, 2019 September 30, 2018 (Dollars in Millions) Beginning Balance $ 335 $ 600 Changes in estimated fair value 129 (162 ) Additions 1,132 125 Payments — (160 ) Ending Balance $ 1,596 $ 403 (1) December 30, 2018 assets and liabilities are all classified as Level 2 with the exception of equity investments of $511 million , which are classified as Level 1 and $335 million, classified as Level 3. (2) Includes $1 million and $6 million of non-current other assets as of September 29, 2019 and December 30, 2018 , respectively. (3) Includes $3 million of non-current other liabilities as of December 30, 2018 . (4) Includes cross currency interest rate swaps and interest rate swaps. (5) Classified as non-current other assets. The carrying amount of the equity investments were $863 million and $511 million as of September 29, 2019 and December 30, 2018 , respectively. (6) Classified within cash equivalents and current marketable securities. (7) Includes $1,453 million (primarily related to Auris Health) and $335 million, classified as non-current other liabilities as of September 29, 2019 and December 30, 2018 , respectively. Includes $143 million classified as current liabilities as of September 29, 2019 The Company's cash, cash equivalents and current marketable securities as of September 29, 2019 comprised: (Dollars in Millions) Carrying Amount Unrecognized Gain Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 2,667 — 2,667 2,667 Other sovereign securities (1) 709 — 709 619 90 U.S. reverse repurchase agreements 6,182 — 6,182 6,182 Other reverse repurchase agreements 241 — 241 241 Corporate debt securities (1) 1,647 — 1,647 1,159 488 Money market funds 1,481 — 1,481 1,481 Time deposits (1) 691 — 691 691 Subtotal 13,618 — 13,618 13,040 578 Unrealized Gain Government securities 4,050 1 4,051 3,195 856 Other sovereign securities 4 — 4 — 4 Corporate debt securities 272 — 272 14 258 Subtotal available for sale debt (2) $ 4,326 1 4,327 3,209 1,118 Total cash, cash equivalents and current marketable securities $ 17,944 1 17,945 16,249 1,696 (1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income. In the fiscal year ended December 30, 2018 the carrying amount was the same as the estimated fair value. Fair value of government securities and obligations and corporate debt securities was estimated using quoted broker prices and significant other observable inputs. The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities. The contractual maturities of the available for sale securities as of September 29, 2019 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 4,267 4,268 Due after one year through five years 59 59 Due after five years through ten years — — Total debt securities $ 4,326 4,327 Financial Instruments not measured at Fair Value: The following financial liabilities are held at carrying amount on the consolidated balance sheet as of September 29, 2019 : (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 2,299 2,349 Non-Current Debt 1.950% Notes due 2020 500 501 3.55% Notes due 2021 449 461 2.45% Notes due 2021 349 354 1.65% Notes due 2021 999 997 0.250% Notes due 2022 (1B Euro 1.0958) 1,094 1,108 2.25% Notes due 2022 997 1,011 6.73% Debentures due 2023 250 298 3.375% Notes due 2023 804 854 2.05% Notes due 2023 498 502 0.650% Notes due 2024 (750MM Euro 1.0958) 819 850 5.50% Notes due 2024 (500 MM GBP 1.2353) 613 752 2.625% Notes due 2025 748 771 2.45% Notes due 2026 1,992 2,028 2.95% Notes due 2027 996 1,052 2.90% Notes due 2028 1,494 1,573 1.150% Notes due 2028 (750MM Euro 1.0958) 815 887 6.95% Notes due 2029 297 416 4.95% Debentures due 2033 498 627 4.375% Notes due 2033 855 1,021 1.650% Notes due 2035 (1.5B Euro 1.0958) 1,628 1,916 3.55% Notes due 2036 989 1,082 5.95% Notes due 2037 992 1,394 3.625% Notes due 2037 1,487 1,656 3.40% Notes due 2038 991 1,073 5.85% Debentures due 2038 696 983 4.50% Debentures due 2040 539 668 4.85% Notes due 2041 297 387 4.50% Notes due 2043 495 629 3.70% Notes due 2046 1,973 2,232 3.75% Notes due 2047 991 1,124 3.50% Notes due 2048 742 817 Other 32 33 Total Non-Current Debt $ 26,919 30,057 The weighted average effective interest rate on non-current debt is 3.20% . The excess of the estimated fair value over the carrying value of debt was $0.3 billion at December 30, 2018. Fair value of the non-current debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 29, 2019
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The worldwide effective income tax rates for the fiscal nine months of 2019 and 2018 were 15.3% an d 17.6% , respectively. During the third fiscal quarter of 2019, the Company recorded a tax benefit from the enactment of Swiss tax reform which reduced the effective rate for the fiscal nine months of 2019 by 3.0% . This benefit was partially offset by the Company increasing its unrecognized tax benefit liability in the current quarter which increased the effective tax rate for the fiscal nine months of 2019 by approximately 2.0% . Additionally, the Company had less income in higher tax jurisdictions relative to lower tax jurisdictions as compared to the same period in 2018. This was primarily driven by the impact of the agreement in principle to settle opioid litigation (see Note 11 to the Consolidated Financial Statements), in the fiscal third quarter of 2019, which was recorded in the U.S., at an effective tax rate of 23% . As of September 29, 2019 , the Company had approximately $3.6 billion of liabilities from unrecognized tax benefits. The Company believes it is possible that tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions outside of the United States. The Company is not able to provide a reasonably reliable estimate of the timing of any future tax payments relating to these uncertain tax positions. With respect to the United States, the IRS has completed its audit for the tax years through 2009 and is currently auditing the tax years 2010 through 2012. The Company has reassessed its uncertain tax positions based on the best information available and therefore in the fiscal third quarter of 2019 has increased its unrecognized tax benefit liability by approximately $0.2 billion . The Company currently expects substantial completion of the audit and settlement of the related tax liabilities in the next nine months. The completion of this tax audit may result in additional adjustments to the Company’s unrecognized tax benefit liability that may have a material impact on the Company’s future operating results or cash flows in the period that the audit is substantially completed. Swiss Tax Reform On September 28, 2018 the Swiss Parliament approved the Federal Act on Tax Reform and AHV Financing (TRAF). On May 19, 2019 a public referendum was held in Switzerland that approved the federal reform proposals. In the fiscal third quarter of 2019, the Swiss Federal Council enacted TRAF. TRAF will become effective on January 1, 2020. The Federal transitional provisions of TRAF allow companies, under certain conditions, to adjust their tax basis adjustments to fair value (i.e., “step-up”) which is used for tax depreciation and amortization purposes resulting in a deduction over the transitional period. The adjustment to the Company’s asset tax basis will require review and approval by the tax authorities. TRAF also provides for parameters which enable the Swiss cantons to establish localized tax rates and regulations for companies. The new cantonal tax parameters include favorable tax benefits for patents and an additional research and development tax deduction. The cantonal transitional provisions of TRAF are also expected to allow companies to elect either 1) tax basis step-up similar to the Federal transition benefit or 2) alternative statutory tax rate for a period not to exceed 5 years. The Company currently has operations located in various Swiss cantons and enactment may not be uniform in both the substantive nature of the legislation and the timing of enactment. The cantons are expected to implement new local legislation by January 1, 2020 or the new federal law will be directly applied. The Company recorded a net tax benefit of $0.4 billion related to this federal and certain cantonal enactments in the fiscal third quarter of 2019 consisting of the following provisions: • approximately $360 million tax expense relating to the remeasurement of Swiss deferred tax assets and liabilities for the change in Federal and cantonal tax rates, where enactment occurred by September 29, 2019. • a $1.2 billion deferred tax asset related to the estimated value of a Federal tax basis step-up of the Company’s Swiss subsidiaries’ assets. • approximately $450 million deferred tax expense relating to U.S. deferred tax liabilities relating to the Global Intangible Low-Taxed Income (GILTI) tax resulting from the remeasurement of the Swiss deferred tax assets and liabilities and the new deferred tax asset for the Federal step-up. See the 2018 Form 10-K for more discussion on the Company’s policy election to account for GILTI under the deferred method. As of September 29, 2019 , two cantons in which the Company operates have enacted legislation in response to the TRAF. The Company is currently assessing the elective cantonal transition provisions including discussions with local taxing authorities on the application of the new law. The Company has recorded an estimated impact of the transitional provisions based on the best available information for cantons where enactment has occurred. The estimated cantonal benefit that has been recorded is not material to the results of the Company. The amounts recorded in the current fiscal quarter do not include the impact of cantonal law changes including the transitional provisions which have not yet been enacted. These enactments, which are expected to occur in the fiscal fourth quarter of 2019 or early 2020, may result in a material impact to the future results of the Company.

Pensions and Other Benefit Plan

Pensions and Other Benefit Plans	9 Months Ended
	Sep. 29, 2019
Retirement Benefits [Abstract]
Pensions and Other Benefit Plans	PENSIONS AND OTHER BENEFIT PLANS Components of Net Periodic Benefit Cost Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans for the fiscal third quarters and the fiscal nine months of 2019 and 2018 include the following components: Fiscal Third Quarter Ended Fiscal Nine Months Ended Retirement Plans Other Benefit Plans Retirement Plans Other Benefit Plans (Dollars in Millions) September 29, 2019 September 30, 2018 September 29, 2019 September 30, 2018 September 29, 2019 September 30, 2018 September 29, 2019 September 30, 2018 Service cost $ 275 307 68 67 828 925 205 202 Interest cost 273 247 46 37 822 748 138 112 Expected return on plan assets (578 ) (550 ) (2 ) (1 ) (1,742 ) (1,664 ) (5 ) (5 ) Amortization of prior service cost/(credit) 1 1 (7 ) (7 ) 3 2 (23 ) (23 ) Recognized actuarial losses 145 213 32 31 435 641 97 92 Curtailments and settlements (4 ) — — — 3 (2 ) — — Net periodic benefit cost $ 112 218 137 127 349 650 412 378 The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings. Company Contributions For the fiscal nine months ended September 29, 2019 , the Company contributed $62 million and $95 million to its U.S. and international retirement plans, respectively. The Company plans to continue to fund its U.S. defined benefit plans to comply with the Pension Protection Act of 2006. International plans are funded in accordance with local regulations.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	9 Months Ended
	Sep. 29, 2019
Equity [Abstract]
Accumulated Other Comprehensive Income	ACCUMULATED OTHER COMPREHENSIVE INCOME Components of other comprehensive income (loss) consist of the following: Foreign Gain/(Loss) Employee Gain/(Loss) Total Accumulated Currency On Benefit On Derivatives Other Comprehensive (Dollars in Millions) Translation Securities Plans & Hedges Income (Loss) December 30, 2018 $ (8,869 ) — (6,158 ) (195 ) (15,222 ) Net change (575 ) 1 442 (179 ) (311 ) September 29, 2019 $ (9,444 ) 1 (5,716 ) (374 ) (15,533 ) Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. Details on reclassifications out of Accumulated Other Comprehensive Income: Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net. Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 6 for additional details. Gain/(Loss) On Derivatives & Hedges - reclassifications to earnings are recorded in the same account as the underlying transaction. See Note 4 for additional details.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 29, 2019
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal third quarters and the fiscal nine months ended September 29, 2019 and September 30, 2018 : Fiscal Third Quarter Ended Fiscal Nine Months Ended (Shares in Millions) September 29, 2019 September 30, 2018 September 29, 2019 September 30, 2018 Basic net earnings per share $ 0.67 1.47 4.19 4.57 Average shares outstanding — basic 2,635.2 2,683.2 2,649.5 2,682.6 Potential shares exercisable under stock option plans 117.8 140.3 137.6 140.9 Less: shares which could be repurchased under treasury stock method (83.8 ) (96.7 ) (99.7 ) (94.7 ) Convertible debt shares 0.7 0.8 0.7 0.8 Average shares outstanding — diluted 2,669.9 2,727.6 2,688.1 2,729.6 Diluted net earnings per share $ 0.66 1.44 4.13 4.49 The diluted net earnings per share calculation for both the fiscal third quarters ended September 29, 2019 and September 30, 2018 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense. The diluted net earnings per share calculation for the fiscal third quarter ended September 29, 2019 excluded 19 million shares related to stock options, as the exercise price of these options was greater than their average market value. The diluted net earnings per share calculation for the fiscal third quarter ended September 30, 2018 included all shares related to stock options, as there were no options or other instruments which were anti-dilutive. The diluted net earnings per share calculation for both the fiscal nine months ended September 29, 2019 and September 30, 2018 included the dilutive effect of convertible debt that was offset by the related reduction in interest expense. The diluted net earnings per share calculation for the fiscal nine months ended September 29, 2019 excluded an insignificant number of shares related to stock options, as the exercise price of these options was greater than their average market value. The diluted net earnings per share calculation for the fiscal nine months ended September 30, 2018 included all shares related to stock options, as there were no

Segments of Business and Geogra

Segments of Business and Geographic Areas	9 Months Ended
	Sep. 29, 2019
Segment Reporting [Abstract]
Segments of Business and Geographic Areas	SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS SALES BY SEGMENT OF BUSINESS Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) September 29, September 30, Percent Change September 29, September 30, Percent Change CONSUMER Baby Care U.S. $ 91 120 (24.1 )% $ 277 306 (9.5 )% International 326 352 (7.3 ) 977 1,079 (9.5 ) Worldwide 417 472 (11.6 ) 1,254 1,385 (9.5 ) Beauty U.S. 559 543 2.9 1,810 1,791 1.1 International 592 535 10.8 1,633 1,480 10.4 Worldwide 1,151 1,078 6.8 3,443 3,271 5.3 Oral Care U.S. 156 158 (1.1 ) 462 472 (2.1 ) International 223 226 (1.6 ) 673 684 (1.7 ) Worldwide 379 384 (1.4 ) 1,135 1,156 (1.8 ) OTC U.S. 477 440 8.4 1,468 1,359 8.0 International 621 608 2.2 1,781 1,827 (2.5 ) Worldwide 1,098 1,048 4.8 3,249 3,186 2.0 Women's Health U.S. 3 3 (4.0 ) 9 10 (3.8 ) International 252 266 (5.4 ) 724 782 (7.5 ) Worldwide 255 269 (5.3 ) 733 792 (7.4 ) Wound Care/Other U.S. 109 106 1.9 343 344 (0.4 ) International 59 58 3.3 173 183 (5.0 ) Worldwide 168 164 2.4 516 527 (2.0 ) TOTAL CONSUMER U.S. 1,394 1,370 1.7 4,369 4,282 2.0 International 2,075 2,045 1.4 5,962 6,035 (1.2 ) Worldwide 3,469 3,415 1.6 10,331 10,317 0.1 PHARMACEUTICAL Immunology U.S. 2,582 2,400 7.6 7,124 6,717 6.1 International 1,129 998 13.2 3,304 3,061 8.0 Worldwide 3,711 3,398 9.3 10,428 9,778 6.7 REMICADE ® U.S. 749 987 (24.1 ) 2,324 2,821 (17.6 ) U.S. Exports 88 100 (12.0 ) 226 346 (34.7 ) International 299 292 2.5 795 921 (13.7 ) Worldwide 1,136 1,379 (17.6 ) 3,345 4,088 (18.2 ) SIMPONI / SIMPONI ARIA ® U.S. 313 281 11.6 857 779 10.0 International 273 255 7.3 816 823 (0.8 ) Worldwide 586 536 9.6 1,673 1,602 4.5 STELARA ® U.S. 1,212 889 36.3 3,152 2,460 28.1 International 487 421 15.7 1,509 1,252 20.5 Worldwide 1,698 1,310 29.6 4,661 3,712 25.6 TREMFYA ® U.S. 221 143 54.3 565 311 81.7% International 69 28 * 177 58 * Worldwide 290 171 69.0 742 369 * OTHER IMMUNOLOGY U.S. — — — — — — International 2 2 (4.4) 8 7 13.7 Worldwide 2 2 (4.4) 8 7 13.7 Infectious Diseases U.S. 418 345 21.2 1,162 1,006 15.5 International 421 478 (12.0 ) 1,385 1,496 (7.4 ) Worldwide 839 823 1.9 2,547 2,502 1.8 EDURANT ® / rilpivirine U.S. 12 13 (7.3 ) 36 42 (14.3 ) International 206 189 9.0 603 581 3.8 Worldwide 218 202 7.9 639 623 2.6 PREZISTA ® / PREZCOBIX ® / REZOLSTA ® / SYMTUZA ® U.S. 373 297 25.4 1,032 847 21.8 International 135 193 (29.8 ) 534 613 (12.8 ) Worldwide 508 490 3.7 1,566 1,460 7.3 OTHER INFECTIOUS DISEASES U.S. 33 35 (4.3 ) 94 117 (19.6 ) International 80 96 (17.4 ) 248 302 (18.2 ) Worldwide 113 131 (13.9 ) 342 419 (18.6 ) Neuroscience U.S. 785 651 20.7 2,172 1,914 13.5 International 810 839 (3.5 ) 2,590 2,663 (2.7 ) Worldwide 1,595 1,490 7.1 4,762 4,577 4.0 CONCERTA ® / methylphenidate U.S. 84 57 48.2 196 191 2.9 International 109 100 9.4 348 322 8.0 Worldwide 193 157 23.5 544 513 6.1 INVEGA SUSTENNA ® / XEPLION ® / INVEGA TRINZA ® / TREVICTA ® U.S. 554 468 18.3 1,543 1,306 18.1 International 297 281 5.9 916 859 6.7 Worldwide 851 749 13.7 2,459 2,165 13.6 RISPERDAL CONSTA ® U.S. 79 76 4.9 237 238 (0.5 ) International 89 99 (10.5 ) 292 321 (9.1 ) Worldwide 167 175 (3.8 ) 528 559 (5.4 ) OTHER NEUROSCIENCE U.S. 68 50 35.3 196 179 9.7 International 316 359 (12.5 ) 1,035 1,161 (10.9 ) Worldwide 384 409 (6.6 ) 1,231 1,340 (8.2 ) Oncology U.S. 1,171 1,250 (6.3 ) 3,146 3,268 (3.7 ) International 1,590 1,338 18.8 4,830 4,087 18.2 Worldwide 2,761 2,588 6.7 7,976 7,355 8.4 DARZALEX ® U.S. 402 318 26.1 1,123 880 27.6 International 363 180 * 1,045 561 86.2 Worldwide 765 498 53.5 2,168 1,441 50.4 IMBRUVICA ® U.S. 447 334 34.0 1,163 811 43.5 International 475 371 27.6 1,373 1,101 24.6 Worldwide 921 705 30.6 2,536 1,912 32.6 VELCADE ® U.S. — — — — — — International 149 271 (44.8 ) 636 864 (26.3 ) Worldwide 149 271 (44.8 ) 636 864 (26.3 ) ZYTIGA ® / abiraterone acetate U.S. 233 527 (55.8 ) 616 1,420 (56.6 ) International 508 431 17.8 1,502 1,292 16.2 Worldwide 741 958 (22.7 ) 2,118 2,712 (21.9 ) OTHER ONCOLOGY U.S. 91 71 26.7 245 157 54.7 International 95 85 12.2 274 269 2.1 Worldwide 186 156 18.8 519 426 21.6 Pulmonary Hypertension U.S. 427 425 0.5 1,296 1,215 6.6 International 227 231 (1.6) 704 691 1.9 Worldwide 654 656 (0.3) 2,000 1,906 4.9 OPSUMIT ® U.S. 206 182 12.9 581 511 13.7 International 140 128 10.1 419 381 10.2 Worldwide 347 310 11.7 1,001 892 12.2 TRACLEER ® / bosentan U.S. 19 69 (72.4) 121 208 (41.8 ) International 46 70 (32.8) 164 214 (23.3 ) Worldwide 65 139 (52.7) 285 422 (32.4 ) UPTRAVI ® U.S. 185 154 20.2 536 433 23.9 International 25 17 52.1 75 49 52.8 Worldwide 210 171 23.4 611 482 26.8 OTHER U.S. 17 20 (10.1) 58 63 (8.9 ) International 15 16 (15.4) 46 47 (3.0 ) Worldwide 31 36 (12.6) 103 110 (6.4 ) Cardiovascular / Metabolism / Other U.S. 955 1,026 (6.9 ) 2,804 3,230 (13.2 ) International 360 365 (1.3 ) 1,131 1,196 (5.4 ) Worldwide 1,316 1,391 (5.4 ) 3,936 4,426 (11.1 ) XARELTO ® U.S. 613 612 0.1 1,704 1,869 (8.9 ) International — — — — — — Worldwide 613 612 0.1 1,704 1,869 (8.9 ) INVOKANA ® / INVOKAMET ® U.S. 125 150 (16.6 ) 411 523 (21.3 ) International 55 40 33.9 147 130 12.3 Worldwide 179 190 (5.8 ) 558 653 (14.6 ) PROCRIT ® / EPREX ® U.S. 126 178 (29.6 ) 387 523 (26.1 ) International 72 77 (5.7 ) 220 244 (9.8 ) Worldwide 198 255 (22.4 ) 607 767 (20.9 ) OTHER U.S. 91 86 8.1 302 315 (3.8 ) International 234 248 (5.7 ) 765 822 (6.9 ) Worldwide 325 334 (2.2 ) 1,067 1,137 (6.1 ) TOTAL PHARMACEUTICAL U.S. 6,340 6,097 4.0 17,705 17,350 2.0 International 4,537 4,249 6.8 13,945 13,194 5.7 Worldwide 10,877 10,346 5.1 31,650 30,544 3.6 MEDICAL DEVICES Diabetes Care U.S. — 125 * — 371 * International — 190 * — 638 * Worldwide — 315 * — 1,009 * Interventional Solutions U.S. 357 320 11.5 1,066 947 12.6 International 382 333 15.3 1,156 1,013 14.2 Worldwide 741 653 13.4 2,223 1,960 13.4 Orthopaedics U.S. 1,301 1,284 1.2 3,950 3,923 0.7 International 837 827 1.2 2,616 2,700 (3.1 ) Worldwide 2,138 2,111 1.2 6,566 6,623 (0.9 ) HIPS U.S. 204 201 1.1 633 621 1.8 International 133 129 2.7 428 432 (0.8 ) Worldwide 336 330 1.7 1,061 1,053 0.7 KNEES U.S. 209 215 (2.7 ) 650 672 (3.3 ) International 136 126 7.9 435 438 (0.6 ) Worldwide 344 341 1.2 1,085 1,110 (2.2 ) TRAUMA U.S. 415 395 5.1 1,239 1,196 3.6 International 262 259 1.0 795 829 (4.1 ) Worldwide 677 654 3.5 2,034 2,025 0.4 SPINE & OTHER U.S. 472 473 (0.2 ) 1,427 1,434 (0.5 ) International 306 313 (2.0 ) 957 1,001 (4.4 ) Worldwide 778 786 (0.9 ) 2,384 2,435 (2.1 ) Surgery U.S. 940 1,016 (7.4 ) 2,867 3,031 (5.4 ) International 1,371 1,360 0.8 4,192 4,283 (2.1 ) Worldwide 2,311 2,376 (2.7 ) 7,059 7,314 (3.5 ) ADVANCED U.S. 409 421 (2.8 ) 1,209 1,216 (0.6 ) International 602 555 8.3 1,811 1,731 4.6 Worldwide 1,010 976 3.6 3,019 2,947 2.4 GENERAL U.S. 443 423 4.7 1,311 1,282 2.3 International 659 657 0.2 1,998 2,094 (4.6 ) Worldwide 1,101 1,080 1.9 3,309 3,376 (2.0 ) SPECIALTY U.S. 88 172 (48.0 ) 347 533 (34.9 ) International 110 148 (25.0 ) 383 458 (16.2 ) Worldwide 200 320 (37.4 ) 731 991 (26.2 ) Vision U.S. 459 452 1.4 1,366 1,351 1.1 International 734 680 8.0 2,117 2,069 2.3 Worldwide 1,193 1,132 5.4 3,483 3,420 1.8 CONTACT LENSES / OTHER U.S. 339 319 6.2 993 948 4.7 International 555 516 7.4 1,566 1,538 1.8 Worldwide 893 835 7.0 2,559 2,486 2.9 SURGICAL U.S. 120 133 (10.0 ) 373 403 (7.4 ) International 180 164 9.9 551 531 3.7 Worldwide 299 297 0.9 923 934 (1.1 ) TOTAL MEDICAL DEVICES U.S. 3,057 3,197 (4.4 ) 9,249 9,623 (3.9 ) International 3,326 3,390 (1.9 ) 10,082 10,703 (5.8 ) Worldwide 6,383 6,587 (3.1 ) 19,331 20,326 (4.9 ) WORLDWIDE U.S. 10,791 10,664 1.2 31,323 31,255 0.2 International 9,938 9,684 2.6 29,989 29,932 0.2 Worldwide $ 20,729 20,348 1.9 % $ 61,312 61,187 0.2 % *Percentage greater than 100% or not meaningful EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) September 29, September 30, Percent Change September 29, September 30, Percent Change Consumer (1) $ 653 510 28.0 % $ 1,800 1,887 (4.6 )% Pharmaceutical (2) (222 ) 2,876 * 5,786 10,193 (43.2 ) Medical Devices (3) 1,392 1,267 9.9 6,078 3,642 66.9 Segment earnings before provision for taxes 1,823 4,653 (60.8 ) 13,664 15,722 (13.1 ) Less: Expense not allocated to segments (4) 176 230 554 845 Worldwide income before tax $ 1,647 4,423 (62.8 )% $ 13,110 14,877 (11.9 )% *Percentage greater than 100% or not meaningful (1) Includes a gain of $0.3 billion related to the Company's previously held equity investment in Ci:z Holdings Co., Ltd. (Dr. Ci: Labo) in the fiscal nine months of 2019. Includes litigation expense of $0.2 billion and restructuring charge of $0.1 billion in the fiscal nine months of 2019. Includes a gain of $0.3 billion from the divestiture of NIZORAL ® in the fiscal nine months of 2018. Includes amortization expense of $0.1 billion in both the fiscal third quarter of 2019 and 2018 and $0.3 billion and $0.2 billion in the fiscal nine months of 2019 and 2018, respectively. (2) Includes litigation expense of $4.0 billion and $4.3 billion primarily related to the agreement in principle to settle opioid litigation in the fiscal third quarter and fiscal nine months of 2019, respectively. Includes an unrealized loss on securities of $0.1 billion in the fiscal third quarter of 2019. Includes an unrealized gain on securities of $0.2 billion , an in-process research and development expense of $0.9 billion related to the Alios asset, a research and development expense of $0.3 billion for an upfront payment related to argenx, Actelion acquisition related costs of $0.1 billion and restructuring charge of $0.1 billion in the fiscal nine months of 2019. Includes an in-process research and development charge of $1.1 billion related to the Alios and XO1 assets and the corresponding XO1 contingent liability reversal of $0.2 billion in the fiscal third quarter and fiscal nine months of 2018. Includes Actelion acquisition related costs of $0.2 billion in the fiscal nine months of 2018 and a gain of $0.1 billion from the divestiture of PANCREASE ® in the fiscal nine months of 2018. Includes amortization expense of $0.8 billion and $0.7 billion in the fiscal third quarters and $2.4 billion and $2.3 billion in the fiscal nine months of 2019 and 2018, respectively. (3) Includes a gain of $2.0 billion from the divestiture of the ASP business in the fiscal nine months of 2019. Includes a restructuring related charge of $0.1 billion and $0.2 billion in the fiscal third quarters of 2019 and 2018, respectively and $0.2 billion and $0.4 billion in the fiscal nine months of 2019 and 2018, respectively. Includes litigation expense of $0.3 billion and $0.7 billion in the fiscal nine months of 2019 and 2018, respectively. Includes amortization expense of $0.2 billion and $0.3 billion in the fiscal third quarters of 2019 and 2018, respectively and $0.7 billion and $0.8 billion in the fiscal nine months of 2019 and 2018, respectively. (4) Amounts not allocated to segments include interest income/expense and general corporate income/expense. SALES BY GEOGRAPHIC AREA Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) September 29, 2019 September 30, 2018 Percent Change September 29, 2019 September 30, 2018 Percent Change United States $ 10,791 10,664 1.2 % $ 31,323 31,255 0.2 % Europe 4,461 4,416 1.0 13,803 14,023 (1.6 ) Western Hemisphere, excluding U.S. 1,488 1,550 (4.0 ) 4,446 4,657 (4.5 ) Asia-Pacific, Africa 3,989 3,718 7.3 11,740 11,252 4.3 Total $ 20,729 20,348 1.9 % $ 61,312 61,187 0.2 %

Business Combinations and Dives

Business Combinations and Divestitures	9 Months Ended
	Sep. 29, 2019
Business Combinations [Abstract]
Business Combinations and Divestitures	BUSINESS COMBINATIONS AND DIVESTITURES On September 27, 2019, the Company acquired the assets of JointPoint, Inc., a privately held company, with navigation software to enable a more digitally-oriented procedure in hips. On April 1, 2019, the Company completed the acquisition of Auris Health, Inc. for approximately $3.4 billion , net of cash acquired. Additional contingent payments of up to $2.35 billion , in the aggregate, may be payable upon reaching certain predetermined milestones. Auris Health was a privately held developer of robotic technologies, initially focused in lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. The Company treated this transaction as a business combination and included it in the Medical Devices segment. The fair value of the acquisition was allocated primarily to amortizable and non-amortizable intangible assets, primarily IPR&D, for $3.0 billion , goodwill for $2.0 billion , marketable securities of $0.2 billion and liabilities assumed of $1.8 billion , which includes the fair value of the contingent payments mentioned above, subject to any subsequent valuation adjustments within the measurement period. The fair value of the contingent consideration was $1.1 billion . A probability of success factor ranging from 55% to 95% was used in the fair value calculation to reflect inherent regulatory and commercial risk of the contingent payments and IPR&D. The discount rate applied was approximately 10% . The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. On April 1, 2019, the Company completed the divestiture of its ASP business to Fortive Corporation for an aggregate value of approximately $2.8 billion , consisting of $2.7 billion of cash proceeds and $0.1 billion of retained net receivables. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $2.0 billion . On October 23, 2018, the Company entered into an agreement to acquire Ci:z Holdings Co., Ltd., (Dr. Ci:Labo) a Japanese company focused on the marketing, development and distribution of a broad range of dermocosmetic, cosmetic and skincare products for a total purchase price of approximately ¥230 billion , which equates to approximately $2.1 billion , using the exchange rate of 109.06 Japanese Yen to each U.S. Dollar on January 16, 2019. The acquisition was completed on January 17, 2019, through a series of transactions that included an all-cash tender offer to acquire the publicly held shares not already held by the Company for ¥5,900 per share. The Company previously held a 20% ownership in Ci:z Holdings Co., Ltd. As of June 2019, the Company became the legal owner of Ci:z Holdings with the completion of the tender offer procedure in Japan. The acquired company was then delisted from the Tokyo Stock Exchange. Additionally, in the fiscal first quarter of 2019, the Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.3 billion related to the Company's previously held equity investment in Ci:z Holdings Co., Ltd. The Company treated this transaction as a business combination and included it in the Consumer segment. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change. At September 29, 2019, the fair value of the acquisition was allocated primarily to amortizable intangible assets for $1.5 billion , goodwill for $1.2 billion and liabilities assumed of $0.4 billion subject to any subsequent valuation adjustments within the measurement period. The adjustments made since the date of acquisition were $0.1 billion to intangible assets, accrued liabilities, deferred taxes on income and property, plant and equipment with the offset to goodwill. The amortizable intangible assets were comprised of brand/trademarks and customer relationships with a weighted average life of 15.3 years . The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. During the fiscal third quarter of 2018, the Company accepted a binding offer to form a strategic collaboration with Jabil Inc., one of the world’s leading manufacturing services providers for health care products and technology products. The Company is expanding a 12-year relationship with Jabil to produce a range of products within the Ethicon Endo-Surgery and DePuy Synthes businesses. This transaction includes the transfer of certain employees and manufacturing sites. Several manufacturing sites were transferred to Jabil in the fiscal nine months of 2019 and the majority of transfers will be completed by year end 2019 with a minor amount remaining in 2020. As of September 29, 2019, the assets held for sale on the Consolidated Balance Sheet were $0.2 billion of inventory. For additional details on the global supply chain restructuring see Note 12 to the Consolidated Financial Statements. During the fiscal third quarter of 2018, the Company completed the acquisitions of Zarbee’s, Inc., a privately held company that is a leader in naturally-based consumer healthcare products and Medical Enterprises Distribution, a healthcare technology firm focused on surgical procedure innovation. During the fiscal second quarter of 2018, the Company completed the acquisition BeneVir Biopharm, Inc. (BeneVir), a privately-held, biopharmaceutical company specializing in the development of oncolytic immunotherapies. Additionally, during the fiscal second quarter of 2018, the Company completed the divestitures of NIZORAL ® , PANCREASE ® and VALCHLOR ®

Legal Proceedings

Legal Proceedings	9 Months Ended
	Sep. 29, 2019
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings	LEGAL PROCEEDINGS Johnson & Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; supplier indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business. The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of September 29, 2019 , the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts already accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors, including whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; or there are numerous parties involved. In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period. PRODUCT LIABILITY Johnson & Johnson and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available. The most significant of these cases include: the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System; the PINNACLE ® Acetabular Cup System; pelvic meshes; RISPERDAL ® ; XARELTO ® ; body powders containing talc, primarily JOHNSONS ® Baby Powder; INVOKANA ® ; and ETHICON PHYSIOMESH ® Flexible Composite Mesh. As of September 29, 2019 , in the United States there were approximately 1,400 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR™ XL Acetabular System and DePuy ASR™ Hip Resurfacing System; 10,500 with respect to the PINNACLE ® Acetabular Cup System; 19,800 with respect to pelvic meshes; 13,600 with respect to RISPERDAL ® ; 30,700 with respect to XARELTO ® ; 16,800 with respect to body powders containing talc; 700 with respect to INVOKANA ® ; and 3,100 with respect to ETHICON PHYSIOMESH ® Flexible Composite Mesh. In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR ™ XL Acetabular System and DePuy ASR ™ Hip Resurfacing System used in hip replacement surgery. Claims for personal injury have been made against DePuy and Johnson & Johnson. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip System plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 31, 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 31, 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, therefore bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle two pending class actions which have been approved by the Québec Superior Court and the Supreme Court of British Columbia. The British Columbia order is currently the subject of an appeal. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and DePuy ASR ™ Hip-related product liability litigation. Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and Johnson & Johnson (collectively, DePuy) relating to the PINNACLE ® Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas. Litigation has also been filed in some state courts and in countries outside of the United States. Several adverse verdicts have been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE ® Acetabular Cup System and the related settlement program. Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and Johnson & Johnson arising out of Ethicon's pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. The MDL Court is remanding cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved a majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company's accruals. In addition, class actions and individual personal injury cases or claims have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands and Belgium, and class actions in Israel, Australia and Canada, seeking damages for alleged injury resulting from Ethicon's pelvic mesh devices. In Australia, a trial of class action issues has been completed and the parties are awaiting a decision. The Company has established accruals with respect to product liability litigation associated with Ethicon's pelvic mesh products. Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH ® Flexible Composite Mesh, claims for personal injury have been made against Ethicon, Inc. and Johnson & Johnson alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) has also been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending outside the United States. Along with ETHICON PHYSIOMESH ® lawsuits, there were a number of filings related to the PROCEED ® Mesh and PROCEED ® Ventral Patch products. In March 2019, the New Jersey Supreme Court entered an order consolidating all PROCEED ® and PROCEED ® Ventral Patch cases as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the US, and in jurisdictions outside the US. The Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH ® Flexible Composite Mesh, PROCEED ® Mesh and PROCEED ® Ventral Patch products. Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and Johnson & Johnson arising out of the use of RISPERDAL ® , indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism, and related compounds. Lawsuits have been primarily filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company including a recent verdict in October 2019 of $8 billion of punitive damages related to one single plaintiff. The Company believes it has strong grounds to overturn this verdict. The Company has settled or otherwise resolved many of the United States cases and the costs associated with these settlements are reflected in the Company's accruals. Claims for personal injury arising out of the use of XARELTO ® , an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); Johnson & Johnson; and JPI's collaboration partner for XARELTO ® Bayer AG and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases have been filed in state courts across the United States. Many of these cases have been consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in California. Class action lawsuits also have been filed in Canada. In March 2019, the Company announced an agreement in principle to the settle the XARELTO ® cases in the United States; such agreement was finalized and executed in May 2019 establishing an ongoing United States settlement program. The Company has established accruals for the costs associated with the United States settlement program and XARELTO ® related product liability litigation. Personal injury claims alleging that talc causes cancer have been made against Johnson & Johnson Consumer Inc. and Johnson & Johnson arising out of the use of body powders containing talc, primarily JOHNSON’S ® Baby Powder. The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Lawsuits have been primarily filed in state courts in Missouri, New Jersey and California, as well as outside the United States. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the District of New Jersey. In the multi-district litigation, the parties have moved to exclude experts, known as Daubert motions. The Court held Daubert hearings in mid-July 2019 and a final round of briefing has been submitted to the Court. The parties are awaiting a decision. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in July 2018 of $4.7 billion . The Company believes that it has strong grounds on appeal to overturn these verdicts. The Company has established an accrual for defense costs only in connection with product liability litigation associated with body powders containing talc. In February 2019, the Company’s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary chapter 11 petition commencing a reorganization under the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to potential liability on account of Imerys’s sales of talc, including to the Company for the Company’s body powders. In its bankruptcy filing, Imerys noted certain claims it alleged it had against the Company for indemnification and rights to joint insurance proceeds. Based on such claims as well as indemnity and insurance claims the Company has against Imerys, the Company petitioned the United States District Court for the District of Delaware to establish federal jurisdiction of the state court talc lawsuits under the “related to” jurisdictional provisions of the Bankruptcy Code. The Company's petition was denied and the state court talc lawsuits that have been removed to federal court on such basis have been remanded. In February 2018, a securities class action lawsuit was filed against Johnson & Johnson and certain named officers in the United States District Court for the District of New Jersey, alleging that Johnson & Johnson violated the federal securities laws by failing to adequately disclose the alleged asbestos contamination in body powders containing talc, primarily JOHNSON'S ® Baby Powder, and that purchasers of Johnson & Johnson’s shares suffered losses as a result. Plaintiffs are seeking damages. The Company has filed a motion to dismiss and awaits the Court’s schedule for oral argument. In October 2018, a shareholder derivative lawsuit was filed against Johnson & Johnson as the nominal defendant and its current directors as defendants in the United States District Court for the District of New Jersey, alleging a breach of fiduciary duties related to the alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S ® Baby Powder, and that Johnson & Johnson has suffered damages as a result of those alleged breaches. In September 2019, the Court granted defendants’ motion to dismiss the shareholder derivative lawsuit, and dismissed the complaint without prejudice. In January 2019, two ERISA class action lawsuits were filed by participants in the Johnson & Johnson Savings Plan against Johnson & Johnson, its Pension and Benefits Committee, and certain named officers in the United States District Court for the District of New Jersey, alleging that the defendants breached their fiduciary duties by offering Johnson & Johnson stock as a Johnson & Johnson Savings Plan investment option when it was imprudent to do so because of failures to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON’S ® Baby Powder. Plaintiffs are seeking damages and injunctive relief. Defendants have filed a motion to dismiss. A lawsuit is pending in the United States District Court for the Central District of California alleging violations of Proposition 65, California’s Unfair Competition Law and False Advertising Law. In June 2019, plaintiffs filed a motion for voluntary dismissal of this Proposition 65 action and the Company opposed such motion to the extent it would allow plaintiffs’ counsel to refile such claims with new plaintiffs. The Court granted plaintiff’s motion conditioned upon payment of attorneys’ fees and costs. Another lawsuit alleging violations of Proposition 65, California’s Consumer Legal Remedies Act, was filed in the Superior Court of California for the County of San Diego. In July 2019, Johnson & Johnson filed a notice of removal to the United States District Court for the Southern District of California. In August 2019, plaintiffs filed an amended complaint in the Southern District and the parties stipulated to having any responsive pleading filed in October 2019. In addition, the Company has received preliminary inquiries and subpoenas to produce documents regarding these matters from Senator Murray, a member of the Senate Committee on Health, Education, Labor and Pensions, the Department of Justice, the Securities and Exchange Commission and the U.S. Congressional Subcommittee on Economic and Consumer Policy. The Company is cooperating with these government inquiries and continues to produce documents in response. Claims for personal injury have been made against a number of Johnson & Johnson companies, including Janssen Pharmaceuticals, Inc. and Johnson & Johnson, arising out of the use of INVOKANA ® , a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. Lawsuits filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in various state courts including Pennsylvania, Louisiana and Utah. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company's accruals. INTELLECTUAL PROPERTY Certain subsidiaries of Johnson & Johnson are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company’s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. The most significant of these matters are described below. Medical Devices In June 2009, Rembrandt Vision Technologies, L.P. (Rembrandt) filed a patent infringement lawsuit against Johnson & Johnson Vision Care, Inc. (JJVCI) in the United States District Court for the Eastern District of Texas alleging that JJVCI's manufacture and sale of its ACUVUE ® ADVANCE and ACUVUE OASYS ® Hydrogel Contact Lenses infringed Rembrandt’s United States Patent No. 5,712,327 and seeking monetary relief. The case was transferred to the United States District Court for the Middle District of Florida, where a trial in May 2012 resulted in a verdict of non-infringement that was subsequently upheld on appeal. In July 2014, Rembrandt sought a new trial based on alleged new evidence, which the district court denied. In April 2016, the Court of Appeals overturned that ruling and remanded the case to the district court for a new trial. A new trial was held in August 2017, and the jury returned a verdict of non-infringement in favor of JJVCI. Rembrandt has appealed the verdict to the United States Court of Appeals for the Federal Circuit (CAFC). In February 2019, the CAFC affirmed the judgment in favor of JJVCI. In March 2013, Medinol Ltd. (Medinol) filed a patent infringement lawsuit against Cordis Corporation (Cordis) and Johnson & Johnson in the United States District Court for the Southern District of New York alleging that Cordis’s sales of the CYPHER ™ and CYPHER SELECT ™ stents made in the United States since 2005 willfully infringed four of Medinol's patents directed to the geometry of articulated stents. Although Johnson & Johnson has since sold Cordis, it has retained liability for this case. After the trial in January 2014, the district court dismissed the case, finding Medinol unreasonably delayed bringing its claims (the laches defense). In September 2014, the district court denied a motion by Medinol to vacate the judgment and grant it a new trial. Medinol appealed the decision to the United States Court of Appeals for the Federal Circuit. In March 2017, the United States Supreme Court held that the laches defense is not available in patent cases. In April 2018, the United States Court of Appeals for the Federal Circuit remanded the case back to the district court to reconsider Medinol’s motion for a new trial. In March 2019, the district court denied Medinol’s motion for a new trial. In April 2019, Medinol filed a notice of appeal. In November 2016, MedIdea, L.L.C. (MedIdea) filed a patent infringement lawsuit against DePuy Orthopaedics, Inc. in the United States District Court for the Northern District of Illinois alleging infringement by the ATTUNE ® Knee System. In April 2017, MedIdea filed an amended complaint adding DePuy Synthes Products, Inc. and DePuy Synthes Sales, Inc. as named defendants (collectively, DePuy). MedIdea alleges infringement of United States Patent Nos. 6,558,426 (’426); 8,273,132 (’132); 8,721,730 (’730) and 9,492,280 (’280) relating to posterior stabilized knee systems. Specifically, MedIdea alleges that the SOFCAM TM Contact feature of the ATTUNE ® posterior stabilized knee products infringes the patents-in-suit. MedIdea is seeking monetary damages and injunctive relief. In June 2017, the case was transferred to the United States District Court for the District of Massachusetts. A claim construction hearing was held in October 2018, and a claim construction order was issued in November 2018. In December 2018, MedIdea stipulated to non-infringement of the ’132, ’730 and ’280 patents, based on the district court’s claim construction and reserving its right to appeal that construction, leaving only the ’426 patent at issue before the district court. In January 2019, the district court stayed the case pending a decision in the Inter Partes Review proceeding on the ’426 patent (see below). In December 2017, DePuy Synthes Products, Inc. filed a petition for Inter Partes Review with the United States Patent and Trademark Office (USPTO), seeking to invalidate the two claims of the ’426 patent asserted in the district court litigation, and in June 2018, the USPTO instituted review of those claims. A hearing was held in March 2019, an d in April 2019, the USPTO issued its decision upholding the validity of the patent. In May 2019, DePuy filed a motion for summary judgment of non-infringement of the claims of the ’426 patent. In December 2016, Ethicon Endo-Surgery, Inc. and Ethicon Endo-Surgery, LLC (now known as Ethicon LLC) sued Covidien, Inc. in the United States District Court for the District of Massachusetts seeking a declaration that United States Patent Nos. 6,585,735 (the ’735 patent); 7,118,587; 7,473,253; 8,070,748 and 8,241,284 (the ’284 patent), are either invalid or not infringed by Ethicon’s ENSEAL ® X1 Large Jaw Tissue Sealer product. In April 2017, Covidien LP, Covidien Sales LLC, and Covidien AG (collectively, Covidien) answered and counterclaimed, denying the allegations, asserting willful infringement of the ’735 patent, the ’284 patent and United States Patent Nos. 8,323,310 (the ’310 patent); 9,084,608; 9,241,759 (the ’759 patent) and 9,113,882, and seeking damages and an injunction. Covidien filed a motion for preliminary injunction, which was denied in October 2017. The parties have entered joint stipulations such that only the ’310 patent and the ’759 patent remain in dispute. Trial began in September 2019 and is expected to conclude in the first quarter of 2020. In December 2016, Dr. Ford Albritton sued Acclarent, Inc. (Acclarent) in United States District Court for the Northern District of Texas alleging that Acclarent’s RELIEVA ® Spin and RELIEVEA SpinPlus ® products infringe U.S. Patent No. 9,011,412 (the ’412 patent). Dr. Albritton also alleges breach of contract, fraud and that he is the true owner of Acclarent’s U.S. Patent No. 8,414,473. In December 2016, Acclarent filed a petition for Inter Partes Review (IPR) with the United States Patent and Trademark Office (USPTO) challenging the validity of the ’412 patent. The USPTO instituted the IPR in July 2017. In July 2018, the USPTO ruled in favor of Albritton in the IPR, finding that Acclarent had not met its burden of proof that the challenged claims were invalid. In October 2019, the Court of Appeals affirmed the USPTO’s Patent Trial and Appeal Board. In June 2019, the parties filed cross motions for summary judgment in the district court and the parties are awaiting a decision. The district court trial is scheduled for April 2020. In November 2017, Board of Regents, The University of Texas System and Tissuegen, Inc. (collectively, UT) filed a lawsuit in the United States District Court for the Western District of Texas against Ethicon, Inc. and Ethicon US, LLC alleging the manufacture and sale of VICRYL ® Plus Antibacterial Sutures, MONOCRYL ® Plus Antibacterial Sutures, PDS ® Plus Antibacterial Sutures, STRATAFIX ® POS ® Antibacterial Sutures and STRATAFIX ® MONOCRYL ® Plus Antibacterial Sutures infringe plaintiffs’ United States Patent Nos. 6,596,296 and 7,033,603 (the ’603 patent) directed to implantable polymer drug releasing biodegradable fibers containing a therapeutic agent. UT is seeking damages and an injunction. In December 2018, Ethicon filed petitions with the USPTO, seeking Inter Partes Review (IPR) of both asserted patents. Those petitions have been stayed by the USPTO pending a decision by the U.S. Supreme Court in an unrelated case. UT dismissed the ’603 patent from the suit. Trial is scheduled for June 2020. In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (“Intuitive”) filed a patent infringement suit against Auris Health, Inc. (“Auris”) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos. 6,246,200 (’200 patent); 6,491,701 (’701 patent); 6,522,906 (’906 patent); 6,800,056 (’056 patent); 8,142,447 (’447 patent); 8,620,473 (’473 patent); 8,801,601 (’601 patent); and 9,452,276 (’276 patent) based on Auris’ Monarch™ Platform. Auris filed Petitions for Inter Partes Review with the USPTO regarding the ’200, ’056, ’601 ’701, ’447, ’276 and ’906 patents. The trial is scheduled to begin in January 2021. In August 2019, RSB Spine LLC (“RSB Spine”) filed a patent infringement suit against DePuy Synthes, Inc. in United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of United States Patent Nos. 6,984,234 and 9,713, 537 by one or more of the following products: Zero-P-VA™ Spacer, Zero-P ® Spacer, Zero- P Natural Plate, Synfix ® LR Spacer and Synfix ® Evolution System. RSB Spine seeks monetary damages and injunctive relief. Pharmaceutical In August 2016, Sandoz Ltd and Hexal AG (collectively, Sandoz) filed a lawsuit in the English High Court against G.D. Searle LLC, a Pfizer company (Searle) and Janssen Sciences Ireland UC (JSI) alleging that Searle’s supplementary protection certificate SPC/GB07/038 (SPC), which is exclusively licensed to JSI, is invalid and should be revoked. Janssen-Cilag Limited sells PREZISTA ® (darunavir) in the United Kingdom pursuant to this license. In October 2016, Searle and JSI counterclaimed against Sandoz for threatened infringement of the SPC based on statements of its plans to launch generic darunavir in the United Kingdom. Sandoz admitted that its generic darunavir product would infringe the SPC if it is found valid. Searle and JSI are seeking an order enjoining Sandoz from marketing its generic darunavir before the expiration of the SPC. Following a trial in April 2017, the court entered a decision holding that the SPC is valid and granting a final injunction. Sandoz has appealed the court’s decision and the injunction is stayed pending the appeal. In January 2018, the court referred the issue on appeal to the Court of Justice for the European Union (CJEU) and stayed the proceedings pending the CJEU’s ruling on the issue. In April 2018, Acerta Pharma B.V., AstraZeneca UK Ltd and AstraZeneca Pharmaceuticals LP filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Pharmacyclics LLC and Abbvie Inc. (collectively, Abbvie), alleging that the manufacture and sale of IMBRUVICA ® infringes U.S. Patent No. 7,459,554. Janssen Biotech, Inc., which commercializes IMBRUVICA ® jointly with Abbvie, intervened in the action in November 2018. A trial is scheduled to begin in January 2021. REMICADE ® Related Cases In August 2014, Celltrion Healthcare Co. Ltd. and Celltrion Inc. (collectively, Celltrion) filed an application with the United States Food and Drug Administration (FDA) for approval to make and sell its own infliximab biosimilar. In March 2015, Janssen Biotech, Inc. (JBI) filed a lawsuit in the United States District Court for the District of Massachusetts against Celltrion and Hospira Healthcare Corporation (Hospira), which has exclusive marketing rights for Celltrion’s infliximab biosimilar in the United States, seeking, among other things, a declaratory judgment that their biosimilar product infringes or potentially infringes several JBI patents, including United States Patent No. 6,284,471 relating to REMICADE ® (infliximab) (the ’471 patent) and United States Patent No. 7,598,083 (the ’083 patent) directed to the cell culture media used to make Celltrion’s biosimilar. In August 2016, the district court granted both Celltrion’s and Hospira’s motions for summary judgment of invalidity of the ’

Restructuring

Restructuring	9 Months Ended
	Sep. 29, 2019
Restructuring and Related Activities [Abstract]
Restructuring	RESTRUCTURING On April 17, 2018, the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions will include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. For additional details on the global supply chain restructuring strategic collaborations see Note 10 to the Consolidated Financial Statements. In the fiscal third quarter of 2019, the Company recorded a pre-tax charge of $128 million , of which $20 million was included in cost of products sold and $39 million was included in other (income) expense. In the fiscal nine months of 2019, the Company recorded a pre-tax charge of $360 million , of which $81 million was included in cost of products sold and $117 million was included in other (income) expense. Total project costs of approximately $598 million have been recorded since the restructuring was announced. See the following table for additional details on the restructuring program. In total, the Company expects these actions to generate approximately $0.6 billion to $0.8 billion in annual pre-tax cost savings that will be substantially delivered by 2022. The Company expects to record pre-tax restructuring charges of approximately $1.9 billion to $2.3 billion , over the 4 to 5 year period of this activity. These costs are associated with network optimizations, exit costs and accelerated depreciation and amortization. The following table summarizes the severance related reserves and the associated spending through the fiscal nine months of 2019: (Dollars in Millions) Severance Asset Write-offs Other** Total Reserve balance, December 30, 2018 $ 194 — 48 242 Current year activity: Charges — 81 279 360 Cash payments (14 ) — (302 ) (316 ) Settled non cash — (81 ) — (81 ) Reserve balance, September 29, 2019* $ 180 — 25 205 *Cash outlays for severance are expected to be substantially paid out over the next 2 years in accordance with the Company's plans and local laws. **Other includes project expense such as salaries for employees supporting the initiative and consulting expenses.

Fair Value Measurements (Polici

Fair Value Measurements (Policies)	9 Months Ended
	Sep. 29, 2019
Fair Value Disclosures [Abstract]
Cash and Cash Equivalents, Policy	The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. Available for sale securities with stated maturities of greater than one year from the date of purchase are available to fund current operations and are classified as cash equivalents and current marketable securities.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 29, 2019
Accounting Policies [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	As noted in the Company’s 2018 10-K, the approximate minimum rental payments required under operating leases that had initial or remaining non-cancelable lease terms in excess of one year at December 30, 2018 were: (Dollars in Millions) 2019 2020 2021 2022 2023 After 2023 Total $223 188 154 116 76 139 896
Schedule of Maturities of Lease Liabilities Related to Operating Leases	The minimum rental payments required under operating leases that have initial or remaining non-cancellable lease terms in excess of one year as of September 29, 2019 are: (Dollars in Millions) Operating Leases 2019 (for the remainder of fiscal 2019) $ 82 2020 274 2021 218 2022 160 2023 106 After 2023 241 Total lease payments 1,081 Less: Interest 89 Present Value of lease liabilities $ 992
Schedule of Supplemental Balance Sheet Information	Supplemental balance sheet information (for the fiscal third quarter ended September 29, 2019) : (Dollars in Millions) Non-current operating lease right-of-use assets $ 963 Current operating lease liabilities 266 Non-current Operating lease liabilities 726 Total operating lease liabilities $ 992

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 29, 2019
Inventory Disclosure [Abstract]
Summary of Inventories	(Dollars in Millions) September 29, 2019 December 30, 2018 Raw materials and supplies $ 1,094 1,114 Goods in process 2,000 2,109 Finished goods 6,079 5,376 Total inventories (1) $ 9,173 8,599 (1) The balance as of September 29, 2019, does not include the assets held for sale related to the strategic collaboration with Jabil Inc. of approximately $0.2 billion . The balance as of December 30, 2018, does not include the assets held for sale related to the divestiture of the Advanced Sterilization Products (ASP) business of approximately $0.2 billion and $0.3 billion related to the strategic collaboration with Jabil Inc.

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	9 Months Ended
	Sep. 29, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	(Dollars in Millions) September 29, 2019 December 30, 2018 Intangible assets with definite lives: Patents and trademarks — gross $ 36,114 35,194 Less accumulated amortization 12,158 9,784 Patents and trademarks — net 23,956 25,410 Customer relationships and other intangibles — gross 21,845 21,334 Less accumulated amortization 9,120 8,323 Customer relationships and other intangibles — net 12,725 13,011 Intangible assets with indefinite lives: Trademarks 6,875 6,937 Purchased in-process research and development (1) 4,290 2,253 Total intangible assets with indefinite lives 11,165 9,190 Total intangible assets — net $ 47,846 47,611 (1) In the fiscal first quarter of 2019, the Company recorded an IPR&D impairment charge of $0.9 billion for the remaining intangible asset value related to the development program of AL-8176, an investigational drug for the treatment of Respiratory Syncytial Virus (RSV) and human metapneumovirus (hMPV) acquired with the 2014 acquisition of Alios Biopharma Inc. The impairment charge was based on additional information, including clinical data, which became available and led to the Company's decision to abandon the development of AL-8176. A partial impairment charge of $0.8 billion was previously recorded in the fiscal third quarter of 2018 related to the development program of AL-8176. In the fiscal second quarter of 2019, the Company completed the acquisition of Auris Health, Inc. and recorded an in-process research and development intangible asset of $2.9 billion .
Goodwill	Goodwill as of September 29, 2019 was allocated by segment of business as follows: (Dollars in Millions) Consumer Pharm Med Devices Total Goodwill at December 30, 2018 $ 8,670 9,063 12,720 30,453 Goodwill, related to acquisitions 1,191 — 2,018 3,209 Currency translation/Other (266 ) (86 ) (19 ) (371 ) Goodwill at September 29, 2019 $ 9,595 8,977 14,719 33,291

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 29, 2019
Fair Value Disclosures [Abstract]
Summary of Derivative Activity	September 29, 2019 September 30, 2018 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $ — — — (3 ) — — — — (7 ) — Derivatives designated as hedging instruments — — — 3 — — — — 7 — Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 39 — — — — 25 — Amount of gain or (loss) recognized in AOCI — — — 39 — — — — 25 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income (8 ) (77 ) 1,911 — 1 4 97 10 — (3 ) Amount of gain or (loss) recognized in AOCI (23 ) (197 ) 1,939 — 5 15 192 (4 ) — (1 ) Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 89 — — — 34 — Amount of gain or (loss) recognized in AOCI $ — — — 159 — — — — 35 — The following table is a summary of the activity related to derivatives and hedges for the fiscal nine months ended in 2019 and 2018 : September 29, 2019 September 30, 2018 (Dollars in Millions) Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense Sales Cost of Products Sold R&D Expense Interest (Income) Expense Other (Income) Expense The effects of fair value, net investment and cash flow hedging: Gain (Loss) on fair value hedging relationship: Interest rate swaps contracts: Hedged items $ — — — (2 ) — — — — 3 — Derivatives designated as hedging instruments — — — 2 — — — — (3 ) — Gain (Loss) on net investment hedging relationship: Cross currency interest rate swaps contracts: Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing — — — 117 — — — — 27 — Amount of gain or (loss) recognized in AOCI — — — 117 — — — — 27 — Gain (Loss) on cash flow hedging relationship: Forward foreign exchange contracts: Amount of gain or (loss) reclassified from AOCI into income (43 ) (213 ) 1,808 — 9 50 175 (242 ) — (24 ) Amount of gain or (loss) recognized in AOCI (29 ) (543 ) 1,847 — 15 (3 ) 138 (220 ) — (16 ) Cross currency interest rate swaps contracts: Amount of gain or (loss) reclassified from AOCI into income — — — 207 — — — — 106 — Amount of gain or (loss) recognized in AOCI $ — — — 299 — — — — 111 — Gain/(Loss) Recognized In Accumulated OCI Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From Accumulated OCI Into Income (Dollars in Millions) September 29, 2019 September 30, 2018 September 29, 2019 September 30, 2018 Debt $ 162 (50 ) Other (income) expense — — Cross Currency interest rate swaps $ 152 (75 ) Other (income) expense — — The following table is the effect of net investment hedges for the fiscal nine months ended in 2019 and 2018 : Gain/(Loss) Recognized In Accumulated OCI Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income Gain/(Loss) Reclassified From Accumulated OCI Into Income (Dollars in Millions) September 29, 2019 September 30, 2018 September 29, 2019 September 30, 2018 Debt $ 176 106 Other (income) expense — — Cross Currency interest rate swaps $ 465 (37 ) Other (income) expense — —
Schedule of Derivatives Recorded in Consolidated Balance Sheet	As of September 29, 2019 , and December 30, 2018 , the following amounts were recorded on the Consolidated Balance Sheet related to cumulative basis adjustment for fair value hedges: Line item in the Consolidated Balance Sheet in which the hedged item is included Carrying Amount of the Hedged Liability Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability (Dollars in Millions) September 29, 2019 December 30, 2018 September 29, 2019 December 30, 2018 Current Portion of Long-term Debt $ 502 494 (2 ) 5 Long-term Debt — — — —
Schedule of Effect of Derivatives not Designated as Hedging Instruments	The following table is the effect of derivatives not designated as hedging instrument for the fiscal third quarter and fiscal nine months ended in 2019 and 2018: Gain/(Loss) Recognized In Income on Derivative Gain/(Loss) Recognized In Income on Derivative (Dollars in Millions) Location of Gain /(Loss) Recognized in Income on Derivative Fiscal Third Quarter Ended Fiscal Nine Months Ended Derivatives Not Designated as Hedging Instruments September 29, 2019 September 30, 2018 September 29, 2019 September 30, 2018 Foreign Exchange Contracts Other (income) expense $ (13 ) 49 (101 ) (23 )
Summary of Activity Related to Equity Investments	The following table is a summary of the activity related to equity investments: (Dollars in Millions) December 30, 2018 September 29, 2019 Carrying Value Changes in Fair Value Reflected in Net Income (1) Sales/ Purchases/Other (2) Carrying Value Non Current Other Assets Equity Investments with readily determinable value $ 511 201 151 863 863 Equity Investments without readily determinable value $ 681 (28 ) 46 699 699 (1) Recorded in Other Income/Expense (2) Other includes impact of currency
Financial Assets and Liabilities at Fair Value	The Company’s significant financial assets and liabilities measured at fair value as of September 29, 2019 and December 30, 2018 were as follows: September 29, 2019 December 30, 2018 (Dollars in Millions) Level 1 Level 2 Level 3 Total Total (1) Derivatives designated as hedging instruments: Assets: Forward foreign exchange contracts $ — 498 — 498 501 Interest rate contracts (2)(4) — 681 — 681 161 Total — 1,179 — 1,179 662 Liabilities: Forward foreign exchange contracts — 635 — 635 548 Interest rate contracts (3)(4) — 410 — 410 292 Total — 1,045 — 1,045 840 Derivatives not designated as hedging instruments: Assets: Forward foreign exchange contracts — 32 — 32 32 Liabilities: Forward foreign exchange contracts — 38 — 38 32 Other Investments: Equity investments (5) 863 — — 863 511 Debt securities (6) $ — 4,327 — 4,327 9,734 Other Liabilities Contingent consideration (7) 1,596 1,596 335 Gross to Net Derivative Reconciliation September 29, 2019 December 30, 2018 (Dollars in Millions) Total Gross Assets $ 1,211 694 Credit Support Agreement (CSA) (1,013 ) (423 ) Total Net Asset 198 271 Total Gross Liabilities 1,083 872 Credit Support Agreement (CSA) (945 ) (605 ) Total Net Liabilities $ 138 267 Summarized information about changes in liabilities for contingent consideration is as follows: Nine months ended September 29, 2019 September 30, 2018 (Dollars in Millions) Beginning Balance $ 335 $ 600 Changes in estimated fair value 129 (162 ) Additions 1,132 125 Payments — (160 ) Ending Balance $ 1,596 $ 403 (1) December 30, 2018 assets and liabilities are all classified as Level 2 with the exception of equity investments of $511 million , which are classified as Level 1 and $335 million, classified as Level 3. (2) Includes $1 million and $6 million of non-current other assets as of September 29, 2019 and December 30, 2018 , respectively. (3) Includes $3 million of non-current other liabilities as of December 30, 2018 . (4) Includes cross currency interest rate swaps and interest rate swaps. (5) Classified as non-current other assets. The carrying amount of the equity investments were $863 million and $511 million as of September 29, 2019 and December 30, 2018 , respectively. (6) Classified within cash equivalents and current marketable securities. (7) Includes $1,453 million (primarily related to Auris Health) and $335 million, classified as non-current other liabilities as of September 29, 2019 and December 30, 2018 , respectively. Includes $143 million classified as current liabilities as of
Marketable Securities	The Company's cash, cash equivalents and current marketable securities as of September 29, 2019 comprised: (Dollars in Millions) Carrying Amount Unrecognized Gain Estimated Fair Value Cash & Cash Equivalents Current Marketable Securities Cash $ 2,667 — 2,667 2,667 Other sovereign securities (1) 709 — 709 619 90 U.S. reverse repurchase agreements 6,182 — 6,182 6,182 Other reverse repurchase agreements 241 — 241 241 Corporate debt securities (1) 1,647 — 1,647 1,159 488 Money market funds 1,481 — 1,481 1,481 Time deposits (1) 691 — 691 691 Subtotal 13,618 — 13,618 13,040 578 Unrealized Gain Government securities 4,050 1 4,051 3,195 856 Other sovereign securities 4 — 4 — 4 Corporate debt securities 272 — 272 14 258 Subtotal available for sale debt (2) $ 4,326 1 4,327 3,209 1,118 Total cash, cash equivalents and current marketable securities $ 17,944 1 17,945 16,249 1,696 (1) Held to maturity investments are reported at amortized cost and gains or losses are reported in earnings. (2) Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.
Schedule of Available for Sale Securities Maturities	The contractual maturities of the available for sale securities as of September 29, 2019 are as follows: (Dollars in Millions) Cost Basis Fair Value Due within one year $ 4,267 4,268 Due after one year through five years 59 59 Due after five years through ten years — — Total debt securities $ 4,326 4,327
Financial Liabilities not Measured at Fair Value	Financial Instruments not measured at Fair Value: The following financial liabilities are held at carrying amount on the consolidated balance sheet as of September 29, 2019 : (Dollars in Millions) Carrying Amount Estimated Fair Value Financial Liabilities Current Debt $ 2,299 2,349 Non-Current Debt 1.950% Notes due 2020 500 501 3.55% Notes due 2021 449 461 2.45% Notes due 2021 349 354 1.65% Notes due 2021 999 997 0.250% Notes due 2022 (1B Euro 1.0958) 1,094 1,108 2.25% Notes due 2022 997 1,011 6.73% Debentures due 2023 250 298 3.375% Notes due 2023 804 854 2.05% Notes due 2023 498 502 0.650% Notes due 2024 (750MM Euro 1.0958) 819 850 5.50% Notes due 2024 (500 MM GBP 1.2353) 613 752 2.625% Notes due 2025 748 771 2.45% Notes due 2026 1,992 2,028 2.95% Notes due 2027 996 1,052 2.90% Notes due 2028 1,494 1,573 1.150% Notes due 2028 (750MM Euro 1.0958) 815 887 6.95% Notes due 2029 297 416 4.95% Debentures due 2033 498 627 4.375% Notes due 2033 855 1,021 1.650% Notes due 2035 (1.5B Euro 1.0958) 1,628 1,916 3.55% Notes due 2036 989 1,082 5.95% Notes due 2037 992 1,394 3.625% Notes due 2037 1,487 1,656 3.40% Notes due 2038 991 1,073 5.85% Debentures due 2038 696 983 4.50% Debentures due 2040 539 668 4.85% Notes due 2041 297 387 4.50% Notes due 2043 495 629 3.70% Notes due 2046 1,973 2,232 3.75% Notes due 2047 991 1,124 3.50% Notes due 2048 742 817 Other 32 33 Total Non-Current Debt $ 26,919 30,057

Pensions and Other Benefit Pl_2

Pensions and Other Benefit Plans (Tables)	9 Months Ended
	Sep. 29, 2019
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Cost	Net periodic benefit costs for the Company’s defined benefit retirement plans and other benefit plans for the fiscal third quarters and the fiscal nine months of 2019 and 2018 include the following components: Fiscal Third Quarter Ended Fiscal Nine Months Ended Retirement Plans Other Benefit Plans Retirement Plans Other Benefit Plans (Dollars in Millions) September 29, 2019 September 30, 2018 September 29, 2019 September 30, 2018 September 29, 2019 September 30, 2018 September 29, 2019 September 30, 2018 Service cost $ 275 307 68 67 828 925 205 202 Interest cost 273 247 46 37 822 748 138 112 Expected return on plan assets (578 ) (550 ) (2 ) (1 ) (1,742 ) (1,664 ) (5 ) (5 ) Amortization of prior service cost/(credit) 1 1 (7 ) (7 ) 3 2 (23 ) (23 ) Recognized actuarial losses 145 213 32 31 435 641 97 92 Curtailments and settlements (4 ) — — — 3 (2 ) — — Net periodic benefit cost $ 112 218 137 127 349 650 412 378

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 29, 2019
Equity [Abstract]
Components of Accumulated Other Comprehensive Income	Components of other comprehensive income (loss) consist of the following: Foreign Gain/(Loss) Employee Gain/(Loss) Total Accumulated Currency On Benefit On Derivatives Other Comprehensive (Dollars in Millions) Translation Securities Plans & Hedges Income (Loss) December 30, 2018 $ (8,869 ) — (6,158 ) (195 ) (15,222 ) Net change (575 ) 1 442 (179 ) (311 ) September 29, 2019 $ (9,444 ) 1 (5,716 ) (374 ) (15,533 )

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 29, 2019
Earnings Per Share [Abstract]
Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share	The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal third quarters and the fiscal nine months ended September 29, 2019 and September 30, 2018 : Fiscal Third Quarter Ended Fiscal Nine Months Ended (Shares in Millions) September 29, 2019 September 30, 2018 September 29, 2019 September 30, 2018 Basic net earnings per share $ 0.67 1.47 4.19 4.57 Average shares outstanding — basic 2,635.2 2,683.2 2,649.5 2,682.6 Potential shares exercisable under stock option plans 117.8 140.3 137.6 140.9 Less: shares which could be repurchased under treasury stock method (83.8 ) (96.7 ) (99.7 ) (94.7 ) Convertible debt shares 0.7 0.8 0.7 0.8 Average shares outstanding — diluted 2,669.9 2,727.6 2,688.1 2,729.6 Diluted net earnings per share $ 0.66 1.44 4.13 4.49

Segments of Business and Geog_2

Segments of Business and Geographic Areas (Tables)	9 Months Ended
	Sep. 29, 2019
Segment Reporting [Abstract]
Sales By Segment Of Business	SALES BY SEGMENT OF BUSINESS Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) September 29, September 30, Percent Change September 29, September 30, Percent Change CONSUMER Baby Care U.S. $ 91 120 (24.1 )% $ 277 306 (9.5 )% International 326 352 (7.3 ) 977 1,079 (9.5 ) Worldwide 417 472 (11.6 ) 1,254 1,385 (9.5 ) Beauty U.S. 559 543 2.9 1,810 1,791 1.1 International 592 535 10.8 1,633 1,480 10.4 Worldwide 1,151 1,078 6.8 3,443 3,271 5.3 Oral Care U.S. 156 158 (1.1 ) 462 472 (2.1 ) International 223 226 (1.6 ) 673 684 (1.7 ) Worldwide 379 384 (1.4 ) 1,135 1,156 (1.8 ) OTC U.S. 477 440 8.4 1,468 1,359 8.0 International 621 608 2.2 1,781 1,827 (2.5 ) Worldwide 1,098 1,048 4.8 3,249 3,186 2.0 Women's Health U.S. 3 3 (4.0 ) 9 10 (3.8 ) International 252 266 (5.4 ) 724 782 (7.5 ) Worldwide 255 269 (5.3 ) 733 792 (7.4 ) Wound Care/Other U.S. 109 106 1.9 343 344 (0.4 ) International 59 58 3.3 173 183 (5.0 ) Worldwide 168 164 2.4 516 527 (2.0 ) TOTAL CONSUMER U.S. 1,394 1,370 1.7 4,369 4,282 2.0 International 2,075 2,045 1.4 5,962 6,035 (1.2 ) Worldwide 3,469 3,415 1.6 10,331 10,317 0.1 PHARMACEUTICAL Immunology U.S. 2,582 2,400 7.6 7,124 6,717 6.1 International 1,129 998 13.2 3,304 3,061 8.0 Worldwide 3,711 3,398 9.3 10,428 9,778 6.7 REMICADE ® U.S. 749 987 (24.1 ) 2,324 2,821 (17.6 ) U.S. Exports 88 100 (12.0 ) 226 346 (34.7 ) International 299 292 2.5 795 921 (13.7 ) Worldwide 1,136 1,379 (17.6 ) 3,345 4,088 (18.2 ) SIMPONI / SIMPONI ARIA ® U.S. 313 281 11.6 857 779 10.0 International 273 255 7.3 816 823 (0.8 ) Worldwide 586 536 9.6 1,673 1,602 4.5 STELARA ® U.S. 1,212 889 36.3 3,152 2,460 28.1 International 487 421 15.7 1,509 1,252 20.5 Worldwide 1,698 1,310 29.6 4,661 3,712 25.6 TREMFYA ® U.S. 221 143 54.3 565 311 81.7% International 69 28 * 177 58 * Worldwide 290 171 69.0 742 369 * OTHER IMMUNOLOGY U.S. — — — — — — International 2 2 (4.4) 8 7 13.7 Worldwide 2 2 (4.4) 8 7 13.7 Infectious Diseases U.S. 418 345 21.2 1,162 1,006 15.5 International 421 478 (12.0 ) 1,385 1,496 (7.4 ) Worldwide 839 823 1.9 2,547 2,502 1.8 EDURANT ® / rilpivirine U.S. 12 13 (7.3 ) 36 42 (14.3 ) International 206 189 9.0 603 581 3.8 Worldwide 218 202 7.9 639 623 2.6 PREZISTA ® / PREZCOBIX ® / REZOLSTA ® / SYMTUZA ® U.S. 373 297 25.4 1,032 847 21.8 International 135 193 (29.8 ) 534 613 (12.8 ) Worldwide 508 490 3.7 1,566 1,460 7.3 OTHER INFECTIOUS DISEASES U.S. 33 35 (4.3 ) 94 117 (19.6 ) International 80 96 (17.4 ) 248 302 (18.2 ) Worldwide 113 131 (13.9 ) 342 419 (18.6 ) Neuroscience U.S. 785 651 20.7 2,172 1,914 13.5 International 810 839 (3.5 ) 2,590 2,663 (2.7 ) Worldwide 1,595 1,490 7.1 4,762 4,577 4.0 CONCERTA ® / methylphenidate U.S. 84 57 48.2 196 191 2.9 International 109 100 9.4 348 322 8.0 Worldwide 193 157 23.5 544 513 6.1 INVEGA SUSTENNA ® / XEPLION ® / INVEGA TRINZA ® / TREVICTA ® U.S. 554 468 18.3 1,543 1,306 18.1 International 297 281 5.9 916 859 6.7 Worldwide 851 749 13.7 2,459 2,165 13.6 RISPERDAL CONSTA ® U.S. 79 76 4.9 237 238 (0.5 ) International 89 99 (10.5 ) 292 321 (9.1 ) Worldwide 167 175 (3.8 ) 528 559 (5.4 ) OTHER NEUROSCIENCE U.S. 68 50 35.3 196 179 9.7 International 316 359 (12.5 ) 1,035 1,161 (10.9 ) Worldwide 384 409 (6.6 ) 1,231 1,340 (8.2 ) Oncology U.S. 1,171 1,250 (6.3 ) 3,146 3,268 (3.7 ) International 1,590 1,338 18.8 4,830 4,087 18.2 Worldwide 2,761 2,588 6.7 7,976 7,355 8.4 DARZALEX ® U.S. 402 318 26.1 1,123 880 27.6 International 363 180 * 1,045 561 86.2 Worldwide 765 498 53.5 2,168 1,441 50.4 IMBRUVICA ® U.S. 447 334 34.0 1,163 811 43.5 International 475 371 27.6 1,373 1,101 24.6 Worldwide 921 705 30.6 2,536 1,912 32.6 VELCADE ® U.S. — — — — — — International 149 271 (44.8 ) 636 864 (26.3 ) Worldwide 149 271 (44.8 ) 636 864 (26.3 ) ZYTIGA ® / abiraterone acetate U.S. 233 527 (55.8 ) 616 1,420 (56.6 ) International 508 431 17.8 1,502 1,292 16.2 Worldwide 741 958 (22.7 ) 2,118 2,712 (21.9 ) OTHER ONCOLOGY U.S. 91 71 26.7 245 157 54.7 International 95 85 12.2 274 269 2.1 Worldwide 186 156 18.8 519 426 21.6 Pulmonary Hypertension U.S. 427 425 0.5 1,296 1,215 6.6 International 227 231 (1.6) 704 691 1.9 Worldwide 654 656 (0.3) 2,000 1,906 4.9 OPSUMIT ® U.S. 206 182 12.9 581 511 13.7 International 140 128 10.1 419 381 10.2 Worldwide 347 310 11.7 1,001 892 12.2 TRACLEER ® / bosentan U.S. 19 69 (72.4) 121 208 (41.8 ) International 46 70 (32.8) 164 214 (23.3 ) Worldwide 65 139 (52.7) 285 422 (32.4 ) UPTRAVI ® U.S. 185 154 20.2 536 433 23.9 International 25 17 52.1 75 49 52.8 Worldwide 210 171 23.4 611 482 26.8 OTHER U.S. 17 20 (10.1) 58 63 (8.9 ) International 15 16 (15.4) 46 47 (3.0 ) Worldwide 31 36 (12.6) 103 110 (6.4 ) Cardiovascular / Metabolism / Other U.S. 955 1,026 (6.9 ) 2,804 3,230 (13.2 ) International 360 365 (1.3 ) 1,131 1,196 (5.4 ) Worldwide 1,316 1,391 (5.4 ) 3,936 4,426 (11.1 ) XARELTO ® U.S. 613 612 0.1 1,704 1,869 (8.9 ) International — — — — — — Worldwide 613 612 0.1 1,704 1,869 (8.9 ) INVOKANA ® / INVOKAMET ® U.S. 125 150 (16.6 ) 411 523 (21.3 ) International 55 40 33.9 147 130 12.3 Worldwide 179 190 (5.8 ) 558 653 (14.6 ) PROCRIT ® / EPREX ® U.S. 126 178 (29.6 ) 387 523 (26.1 ) International 72 77 (5.7 ) 220 244 (9.8 ) Worldwide 198 255 (22.4 ) 607 767 (20.9 ) OTHER U.S. 91 86 8.1 302 315 (3.8 ) International 234 248 (5.7 ) 765 822 (6.9 ) Worldwide 325 334 (2.2 ) 1,067 1,137 (6.1 ) TOTAL PHARMACEUTICAL U.S. 6,340 6,097 4.0 17,705 17,350 2.0 International 4,537 4,249 6.8 13,945 13,194 5.7 Worldwide 10,877 10,346 5.1 31,650 30,544 3.6 MEDICAL DEVICES Diabetes Care U.S. — 125 * — 371 * International — 190 * — 638 * Worldwide — 315 * — 1,009 * Interventional Solutions U.S. 357 320 11.5 1,066 947 12.6 International 382 333 15.3 1,156 1,013 14.2 Worldwide 741 653 13.4 2,223 1,960 13.4 Orthopaedics U.S. 1,301 1,284 1.2 3,950 3,923 0.7 International 837 827 1.2 2,616 2,700 (3.1 ) Worldwide 2,138 2,111 1.2 6,566 6,623 (0.9 ) HIPS U.S. 204 201 1.1 633 621 1.8 International 133 129 2.7 428 432 (0.8 ) Worldwide 336 330 1.7 1,061 1,053 0.7 KNEES U.S. 209 215 (2.7 ) 650 672 (3.3 ) International 136 126 7.9 435 438 (0.6 ) Worldwide 344 341 1.2 1,085 1,110 (2.2 ) TRAUMA U.S. 415 395 5.1 1,239 1,196 3.6 International 262 259 1.0 795 829 (4.1 ) Worldwide 677 654 3.5 2,034 2,025 0.4 SPINE & OTHER U.S. 472 473 (0.2 ) 1,427 1,434 (0.5 ) International 306 313 (2.0 ) 957 1,001 (4.4 ) Worldwide 778 786 (0.9 ) 2,384 2,435 (2.1 ) Surgery U.S. 940 1,016 (7.4 ) 2,867 3,031 (5.4 ) International 1,371 1,360 0.8 4,192 4,283 (2.1 ) Worldwide 2,311 2,376 (2.7 ) 7,059 7,314 (3.5 ) ADVANCED U.S. 409 421 (2.8 ) 1,209 1,216 (0.6 ) International 602 555 8.3 1,811 1,731 4.6 Worldwide 1,010 976 3.6 3,019 2,947 2.4 GENERAL U.S. 443 423 4.7 1,311 1,282 2.3 International 659 657 0.2 1,998 2,094 (4.6 ) Worldwide 1,101 1,080 1.9 3,309 3,376 (2.0 ) SPECIALTY U.S. 88 172 (48.0 ) 347 533 (34.9 ) International 110 148 (25.0 ) 383 458 (16.2 ) Worldwide 200 320 (37.4 ) 731 991 (26.2 ) Vision U.S. 459 452 1.4 1,366 1,351 1.1 International 734 680 8.0 2,117 2,069 2.3 Worldwide 1,193 1,132 5.4 3,483 3,420 1.8 CONTACT LENSES / OTHER U.S. 339 319 6.2 993 948 4.7 International 555 516 7.4 1,566 1,538 1.8 Worldwide 893 835 7.0 2,559 2,486 2.9 SURGICAL U.S. 120 133 (10.0 ) 373 403 (7.4 ) International 180 164 9.9 551 531 3.7 Worldwide 299 297 0.9 923 934 (1.1 ) TOTAL MEDICAL DEVICES U.S. 3,057 3,197 (4.4 ) 9,249 9,623 (3.9 ) International 3,326 3,390 (1.9 ) 10,082 10,703 (5.8 ) Worldwide 6,383 6,587 (3.1 ) 19,331 20,326 (4.9 ) WORLDWIDE U.S. 10,791 10,664 1.2 31,323 31,255 0.2 International 9,938 9,684 2.6 29,989 29,932 0.2 Worldwide $ 20,729 20,348 1.9 % $ 61,312 61,187 0.2 % *Percentage greater than 100% or not meaningful
Operating Profit by Segment of Business	EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) September 29, September 30, Percent Change September 29, September 30, Percent Change Consumer (1) $ 653 510 28.0 % $ 1,800 1,887 (4.6 )% Pharmaceutical (2) (222 ) 2,876 * 5,786 10,193 (43.2 ) Medical Devices (3) 1,392 1,267 9.9 6,078 3,642 66.9 Segment earnings before provision for taxes 1,823 4,653 (60.8 ) 13,664 15,722 (13.1 ) Less: Expense not allocated to segments (4) 176 230 554 845 Worldwide income before tax $ 1,647 4,423 (62.8 )% $ 13,110 14,877 (11.9 )% *Percentage greater than 100% or not meaningful (1) Includes a gain of $0.3 billion related to the Company's previously held equity investment in Ci:z Holdings Co., Ltd. (Dr. Ci: Labo) in the fiscal nine months of 2019. Includes litigation expense of $0.2 billion and restructuring charge of $0.1 billion in the fiscal nine months of 2019. Includes a gain of $0.3 billion from the divestiture of NIZORAL ® in the fiscal nine months of 2018. Includes amortization expense of $0.1 billion in both the fiscal third quarter of 2019 and 2018 and $0.3 billion and $0.2 billion in the fiscal nine months of 2019 and 2018, respectively. (2) Includes litigation expense of $4.0 billion and $4.3 billion primarily related to the agreement in principle to settle opioid litigation in the fiscal third quarter and fiscal nine months of 2019, respectively. Includes an unrealized loss on securities of $0.1 billion in the fiscal third quarter of 2019. Includes an unrealized gain on securities of $0.2 billion , an in-process research and development expense of $0.9 billion related to the Alios asset, a research and development expense of $0.3 billion for an upfront payment related to argenx, Actelion acquisition related costs of $0.1 billion and restructuring charge of $0.1 billion in the fiscal nine months of 2019. Includes an in-process research and development charge of $1.1 billion related to the Alios and XO1 assets and the corresponding XO1 contingent liability reversal of $0.2 billion in the fiscal third quarter and fiscal nine months of 2018. Includes Actelion acquisition related costs of $0.2 billion in the fiscal nine months of 2018 and a gain of $0.1 billion from the divestiture of PANCREASE ® in the fiscal nine months of 2018. Includes amortization expense of $0.8 billion and $0.7 billion in the fiscal third quarters and $2.4 billion and $2.3 billion in the fiscal nine months of 2019 and 2018, respectively. (3) Includes a gain of $2.0 billion from the divestiture of the ASP business in the fiscal nine months of 2019. Includes a restructuring related charge of $0.1 billion and $0.2 billion in the fiscal third quarters of 2019 and 2018, respectively and $0.2 billion and $0.4 billion in the fiscal nine months of 2019 and 2018, respectively. Includes litigation expense of $0.3 billion and $0.7 billion in the fiscal nine months of 2019 and 2018, respectively. Includes amortization expense of $0.2 billion and $0.3 billion in the fiscal third quarters of 2019 and 2018, respectively and $0.7 billion and $0.8 billion in the fiscal nine months of 2019 and 2018, respectively. (4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	SALES BY GEOGRAPHIC AREA Fiscal Third Quarter Ended Fiscal Nine Months Ended (Dollars in Millions) September 29, 2019 September 30, 2018 Percent Change September 29, 2019 September 30, 2018 Percent Change United States $ 10,791 10,664 1.2 % $ 31,323 31,255 0.2 % Europe 4,461 4,416 1.0 13,803 14,023 (1.6 ) Western Hemisphere, excluding U.S. 1,488 1,550 (4.0 ) 4,446 4,657 (4.5 ) Asia-Pacific, Africa 3,989 3,718 7.3 11,740 11,252 4.3 Total $ 20,729 20,348 1.9 % $ 61,312 61,187 0.2 %

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Sep. 29, 2019
Restructuring and Related Activities [Abstract]
Schedule of Restructuring Reserve	The following table summarizes the severance related reserves and the associated spending through the fiscal nine months of 2019: (Dollars in Millions) Severance Asset Write-offs Other** Total Reserve balance, December 30, 2018 $ 194 — 48 242 Current year activity: Charges — 81 279 360 Cash payments (14 ) — (302 ) (316 ) Settled non cash — (81 ) — (81 ) Reserve balance, September 29, 2019* $ 180 — 25 205 *Cash outlays for severance are expected to be substantially paid out over the next 2 years in accordance with the Company's plans and local laws. **Other includes project expense such as salaries for employees supporting the initiative and consulting expenses.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Narrative (Details) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 29, 2019USD ($)	Sep. 29, 2019USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Weighted average remaining lease term	5 years 9 months 18 days	5 years 9 months 18 days
Weighted average discount rate	3.00%	3.00%
Operating lease costs	$ 103	$ 227
Operating lease payments	$ 86	$ 233
Minimum | Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease, term of contract	1 year	1 year
Maximum | Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease, term of contract	55 years	55 years

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Schedule of Future Minimum Rental Payments for Operating Leases (Details) $ in Millions	Dec. 30, 2018USD ($)
Accounting Policies [Abstract]
2019	$ 223
2020	188
2021	154
2022	116
2023	76
After 2023	139
Total	$ 896

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Maturities of Lease Liabilities Related to Operating Leases (Details) $ in Millions	Sep. 29, 2019USD ($)
Accounting Policies [Abstract]
2019 (for the remainder of fiscal 2019)	$ 82
2020	274
2021	218
2022	160
2023	106
After 2023	241
Total lease payments	1,081
Less: Interest	89
Present Value of lease liabilities	$ 992

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Supplemental Balance Sheet Information (Details) $ in Millions	Sep. 29, 2019USD ($)
Accounting Policies [Abstract]
Non-current operating lease right-of-use assets	$ 963
Current operating lease liabilities	266
Non-current Operating lease liabilities	726
Total operating lease liabilities	$ 992

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Sep. 29, 2019	Dec. 30, 2018
Summary of Inventories
Raw materials and supplies	$ 1,094	$ 1,114
Goods in process	2,000	2,109
Finished goods	6,079	5,376
Total inventories	9,173	8,599
AdvancedSterilizationProducts | Discontinued Operations, Held-for-sale or Disposed of by Sale
Summary of Inventories
Assets held for sale, current		200
Supply Chain | Discontinued Operations, Held-for-sale or Disposed of by Sale
Summary of Inventories
Assets held for sale, current	$ 200	$ 300

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 29, 2019	Mar. 31, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018	Dec. 30, 2018
Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$ 1,100		$ 1,100	$ 3,300	$ 3,300
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	11,165			11,165		$ 9,190
Total intangible assets - net	47,846			47,846		47,611
Trademarks
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	6,875			6,875		6,937
Purchased In-Process Research And Development
Intangible assets with indefinite lives:
Indefinite-Lived Intangible Assets	4,290			4,290		2,253
Patents And Trademarks
Intangible assets with definite lives:
Finite-Lived Intangible Assets, Gross	36,114			36,114		35,194
Less accumulated amortization	12,158			12,158		9,784
Finite-Lived Intangible Assets, Net	23,956			23,956		25,410
Customer relationships and other intangible assets
Intangible assets with definite lives:
Finite-Lived Intangible Assets, Gross	21,845			21,845		21,334
Less accumulated amortization	9,120			9,120		8,323
Finite-Lived Intangible Assets, Net	$ 12,725			$ 12,725		$ 13,011
Alios Biopharma Inc | Purchased In-Process Research And Development
Intangible assets with indefinite lives:
Impairment charge		$ 900	$ 800

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Goodwill By Segment (Details) $ in Millions	9 Months Ended
	Sep. 29, 2019USD ($)
Goodwill [Roll Forward]
Goodwill Beginning of Period	$ 30,453
Goodwill, related to acquisitions	3,209
Currency translation/Other	(371)
Goodwill End of Period	33,291
CONSUMER
Goodwill [Roll Forward]
Goodwill Beginning of Period	8,670
Goodwill, related to acquisitions	1,191
Currency translation/Other	(266)
Goodwill End of Period	9,595
PHARMACEUTICAL
Goodwill [Roll Forward]
Goodwill Beginning of Period	9,063
Goodwill, related to acquisitions	0
Currency translation/Other	(86)
Goodwill End of Period	8,977
Medical Devices
Goodwill [Roll Forward]
Goodwill Beginning of Period	12,720
Goodwill, related to acquisitions	2,018
Currency translation/Other	(19)
Goodwill End of Period	$ 14,719

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill - Narrative (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 29, 2019	Mar. 31, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018	Jun. 30, 2019	Apr. 01, 2019	Dec. 30, 2018
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$ 4,400			$ 4,400
Finite-Lived Intangible Assets, Amortization Expense, Year Two	4,400			4,400
Finite-Lived Intangible Assets, Amortization Expense, Year Three	4,400			4,400
Finite-Lived Intangible Assets, Amortization Expense, Year Four	4,400			4,400
Finite-Lived Intangible Assets, Amortization Expense, Year Five	4,400			4,400
Indefinite-lived Intangible Assets (Excluding Goodwill)	11,165			11,165				$ 9,190
Intangible Assets and Goodwill (Textuals)
Amortization expense of amortizable intangible assets	1,100		$ 1,100	3,300	$ 3,300
Goodwill	33,291			33,291				30,453
Patents And Trademarks
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Net	23,956			$ 23,956				25,410
Intangible Assets and Goodwill (Textuals)
Finite-Lived Intangible Assets, Weighted-Average Useful Life				12 years
Customer relationships and other intangible assets
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Net	12,725			$ 12,725				13,011
Intangible Assets and Goodwill (Textuals)
Finite-Lived Intangible Assets, Weighted-Average Useful Life				21 years
Consumer
Intangible Assets and Goodwill (Textuals)
Goodwill	9,595			$ 9,595				8,670
PHARMACEUTICAL
Intangible Assets and Goodwill (Textuals)
Goodwill	8,977			8,977				9,063
Medical Devices
Intangible Assets and Goodwill (Textuals)
Goodwill	14,719			14,719				12,720
Purchased In-Process Research And Development
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 4,290			$ 4,290				$ 2,253
Alios Biopharma Inc | Purchased In-Process Research And Development
Finite-Lived Intangible Assets [Line Items]
Impairment charge		$ 900	$ 800
Auris Health
Intangible Assets and Goodwill (Textuals)
Goodwill							$ 2,000
Auris Health | Purchased In-Process Research And Development
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)						$ 2,900

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018	Dec. 30, 2018	Dec. 31, 2017
Derivative [Line Items]
Available-for-sale Securities, Equity Securities	$ 863		$ 863		$ 511
Accumulated other comprehensive income on derivatives, after tax	(374)		$ (374)
Reclassification of foreign exchange contracts into earnings, period			next 12 months
Maximum length of time for hedge exposure			18 months
Unrealized gains on equity investments	$ 0	$ 0	$ 1	$ 0
Weighted average interest rate on non-current debt	3.20%		3.20%
Excess of the estimated fair value over the carrying value of debt					300
Business Combination, Contingent Consideration, Liability	$ 1,596		$ 1,596		335
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	1,596	403	1,596	403	335	$ 600
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements			0	(160)
Business Combination, Consideration Transferred, Liabilities Incurred			1,132	125
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability			129	(162)
Forward foreign exchange contracts
Derivative [Line Items]
Collateral Already Posted, Aggregate Fair Value	68		68
Derivative notional amounts outstanding	47,300		47,300		41,100
Cross currency interest rate swaps
Derivative [Line Items]
Derivative notional amounts outstanding	18,800		18,800		7,300
Interest Rate Contract
Derivative [Line Items]
Derivative Liability, Noncurrent					3
Derivative notional amounts outstanding	500		500		500
Derivative Asset, Noncurrent	1		1		6
Equity Securities
Derivative [Line Items]
Available-for-sale Securities, Equity Securities	863		863		511
Equity Investments without readily determinable value | Equity Securities
Derivative [Line Items]
Equity, Fair Value Adjustment, Impairment Loss			(29)
Changes in fair value, changes in observable prices			1
Other (income) expense
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0
Fair Value Hedging [Member] | Sales [Member] | Cross currency interest rate swaps
Derivative [Line Items]
Derivative, Excluded Component, Gain (Loss), Recognized in Earnings	0	0	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0	0	0
Fair Value Hedging [Member] | Sales [Member] | Interest Rate Contract
Derivative [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	0	0	0	0
Fair Value Hedging [Member] | Cost of Sales [Member] | Cross currency interest rate swaps
Derivative [Line Items]
Derivative, Excluded Component, Gain (Loss), Recognized in Earnings	0	0	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0	0	0
Fair Value Hedging [Member] | Cost of Sales [Member] | Interest Rate Contract
Derivative [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	0	0	0	0
Fair Value Hedging [Member] | Research and Development Expense [Member] | Cross currency interest rate swaps
Derivative [Line Items]
Derivative, Excluded Component, Gain (Loss), Recognized in Earnings	0	0	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0	0	0
Fair Value Hedging [Member] | Research and Development Expense [Member] | Interest Rate Contract
Derivative [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	0	0	0	0
Fair Value Hedging [Member] | Interest Income Expense Net Member | Cross currency interest rate swaps
Derivative [Line Items]
Derivative, Excluded Component, Gain (Loss), Recognized in Earnings	39	25	117	27
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	39	25	117	27
Fair Value Hedging [Member] | Interest Income Expense Net Member | Interest Rate Contract
Derivative [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	(3)	(7)	(2)	3
Fair Value Hedging [Member] | Other (income) expense | Cross currency interest rate swaps
Derivative [Line Items]
Derivative, Excluded Component, Gain (Loss), Recognized in Earnings	0	0	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0	0	0
Fair Value Hedging [Member] | Other (income) expense | Interest Rate Contract
Derivative [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	0	0	0	0
Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | Sales [Member] | Interest Rate Contract
Derivative [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	0	0	0	0
Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | Cost of Sales [Member] | Interest Rate Contract
Derivative [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	0	0	0	0
Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | Research and Development Expense [Member] | Interest Rate Contract
Derivative [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	0	0	0	0
Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | Interest Income Expense Net Member | Interest Rate Contract
Derivative [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	3	7	2	(3)
Fair Value Hedging [Member] | Designated as Hedging Instrument [Member] | Other (income) expense | Interest Rate Contract
Derivative [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	0	0	0	$ 0
Cash Flow Hedging [Member] | Sales [Member] | Forward foreign exchange contracts
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	(8)	4
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	(23)	15
Cash Flow Hedging [Member] | Sales [Member] | Cross currency interest rate swaps
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0
Cash Flow Hedging [Member] | Cost of Sales [Member] | Forward foreign exchange contracts
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	(77)	97
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	(197)	192
Cash Flow Hedging [Member] | Cost of Sales [Member] | Cross currency interest rate swaps
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0
Cash Flow Hedging [Member] | Research and Development Expense [Member] | Forward foreign exchange contracts
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	1,911	10
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	1,939	(4)
Cash Flow Hedging [Member] | Research and Development Expense [Member] | Cross currency interest rate swaps
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0
Cash Flow Hedging [Member] | Interest Income Expense Net Member | Forward foreign exchange contracts
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	0
Cash Flow Hedging [Member] | Interest Income Expense Net Member | Cross currency interest rate swaps
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	89	34
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	159	35
Cash Flow Hedging [Member] | Other (income) expense | Forward foreign exchange contracts
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	1	(3)
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	5	(1)
Cash Flow Hedging [Member] | Other (income) expense | Cross currency interest rate swaps
Derivative [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax	0	$ 0
Other Noncurrent Liabilities
Derivative [Line Items]
Business Combination, Contingent Consideration, Liability	1,453		1,453		$ 335
Other Current Liabilities
Derivative [Line Items]
Business Combination, Contingent Consideration, Liability	$ 143		$ 143

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Derivative Activity (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018	Dec. 30, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Business Combination, Contingent Consideration, Liability	$ 1,596		$ 1,596		$ 335
Summary of designated derivatives
Gain/ (Loss) reclassified from Accumulated OCI into income	1,955	$ 166	1,885	$ 91
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax	1,922	262	1,706	37
Interest Rate Contract
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Notional Amount	500		500		500
Forward foreign exchange contracts
Derivative Instruments, Gain (Loss) [Line Items]
Collateral Already Posted, Aggregate Fair Value	68		68
Derivative, Notional Amount	47,300		47,300		41,100
Cross currency interest rate swaps
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Notional Amount	18,800		18,800		$ 7,300
Fair Value Hedging | Interest Rate Contract | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	0	0	0	0
Fair Value Hedging | Interest Rate Contract | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	0	0	0	0
Fair Value Hedging | Interest Rate Contract | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	0	0	0	0
Fair Value Hedging | Interest Rate Contract | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	0	0	0	0
Fair Value Hedging | Interest Rate Contract | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	(3)	(7)	(2)	3
Fair Value Hedging | Cross currency interest rate swaps | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	0	0	0	0
Unrealized gain (loss) arising during period	0	0	0	0
Fair Value Hedging | Cross currency interest rate swaps | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	0	0	0	0
Unrealized gain (loss) arising during period	0	0	0	0
Fair Value Hedging | Cross currency interest rate swaps | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	0	0	0	0
Unrealized gain (loss) arising during period	0	0	0	0
Fair Value Hedging | Cross currency interest rate swaps | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	0	0	0	0
Unrealized gain (loss) arising during period	0	0	0	0
Fair Value Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net	39	25	117	27
Unrealized gain (loss) arising during period	39	25	117	27
Fair Value Hedging | Designated as Hedging Instrument | Interest Rate Contract | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	0	0	0	0
Fair Value Hedging | Designated as Hedging Instrument | Interest Rate Contract | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	0	0	0	0
Fair Value Hedging | Designated as Hedging Instrument | Interest Rate Contract | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	0	0	0	0
Fair Value Hedging | Designated as Hedging Instrument | Interest Rate Contract | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	0	0	0	0
Fair Value Hedging | Designated as Hedging Instrument | Interest Rate Contract | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	3	7	2	(3)
Cash Flow Hedging | Forward foreign exchange contracts | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	(23)	15
Summary of designated derivatives
Gain/ (Loss) reclassified from Accumulated OCI into income			(43)	50
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax			(29)	(3)
Cash Flow Hedging | Forward foreign exchange contracts | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	(197)	192
Summary of designated derivatives
Gain/ (Loss) reclassified from Accumulated OCI into income			(213)	175
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax			(543)	138
Cash Flow Hedging | Forward foreign exchange contracts | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	1,939	(4)
Summary of designated derivatives
Gain/ (Loss) reclassified from Accumulated OCI into income			1,808	(242)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax			1,847	(220)
Cash Flow Hedging | Forward foreign exchange contracts | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	5	(1)
Summary of designated derivatives
Gain/ (Loss) reclassified from Accumulated OCI into income			9	(24)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax			15	(16)
Cash Flow Hedging | Forward foreign exchange contracts | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	0	0
Summary of designated derivatives
Gain/ (Loss) reclassified from Accumulated OCI into income			0	0
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax			0	0
Cash Flow Hedging | Cross currency interest rate swaps | Sales to customers
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	0	0
Summary of designated derivatives
Gain/ (Loss) reclassified from Accumulated OCI into income			0	0
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax			0	0
Cash Flow Hedging | Cross currency interest rate swaps | Cost of products sold
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	0	0
Summary of designated derivatives
Gain/ (Loss) reclassified from Accumulated OCI into income			0	0
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax			0	0
Cash Flow Hedging | Cross currency interest rate swaps | Research and Development Expense
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	0	0
Summary of designated derivatives
Gain/ (Loss) reclassified from Accumulated OCI into income			0	0
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax			0	0
Cash Flow Hedging | Cross currency interest rate swaps | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	0	0
Summary of designated derivatives
Gain/ (Loss) reclassified from Accumulated OCI into income			0	0
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax			0	0
Cash Flow Hedging | Cross currency interest rate swaps | Interest (income)/Interest expense, net
Derivative Instruments, Gain (Loss) [Line Items]
Unrealized gain (loss) arising during period	$ 159	$ 35
Summary of designated derivatives
Gain/ (Loss) reclassified from Accumulated OCI into income			207	106
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax			$ 299	$ 111

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheet (Details) - USD ($) $ in Millions	Sep. 29, 2019	Dec. 30, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Business Combination, Contingent Consideration, Liability	$ 1,596	$ 335
Carrying Amount of the Hedged Liability	138	267
Current Portion of Long-term Debt
Derivative Instruments, Gain (Loss) [Line Items]
Carrying Amount of the Hedged Liability	502	494
Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability	(2)	5
Long-term Debt
Derivative Instruments, Gain (Loss) [Line Items]
Carrying Amount of the Hedged Liability	0	0
Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability	$ 0	$ 0

Fair Value Measurements - Sch_2

Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018	Dec. 30, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Business Combination, Contingent Consideration, Liability	$ 1,596		$ 1,596		$ 335
Not Designated as Hedging Instrument | Forward foreign exchange contracts | Other (income) expense
Derivative Instruments, Gain (Loss) [Line Items]
Gain/(Loss) Recognized In Income on Derivative	$ (13)	$ 49	$ (101)	$ (23)

Fair Value Measurements - Sch_3

Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018	Dec. 30, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Business Combination, Contingent Consideration, Liability	$ 1,596		$ 1,596		$ 335
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax	162	$ (50)
Gain/(Loss) Recognized In Accumulated OCI			176	$ 106
Sale of Subsidiary Gain (Loss)
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0
Gain/(Loss) Reclassified From Accumulated OCI Into Income			0	0
Other Income Expense Net
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred	0	0
Gain/(Loss) Reclassified From Accumulated OCI Into Income			0	0
Cross Currency Interest Rate Contract
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax	$ 152	$ (75)
Gain/(Loss) Recognized In Accumulated OCI			$ 465	$ (37)

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Activity Related to Equity Investments (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 29, 2019	Dec. 30, 2018
Other Investment Not Readily Marketable [Line Items]
Business Combination, Contingent Consideration, Liability	$ 1,596	$ 335
Equity Investment [Roll Forward]
Non Current Other Assets	5,307	$ 4,182
Equity Securities | Equity Investments with readily determinable value
Equity Investment [Roll Forward]
Carrying value, beginning of period	511
Changes in Fair Value Reflected in Net Income	201
Sales/ Purchases/Other	151
Carrying value, end of period	863
Non Current Other Assets	863
Equity Securities | Equity Investments without readily determinable value
Equity Investment [Roll Forward]
Carrying value, beginning of period	681
Changes in Fair Value Reflected in Net Income	(28)
Sales/ Purchases/Other	46
Carrying value, end of period	699
Non Current Other Assets	$ 699

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($) $ in Millions	Sep. 29, 2019	Dec. 30, 2018
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	$ 1,179
Derivatives designated as hedging instruments : Liabilities	1,045
Available-for-sale Securities, Equity Securities	863	$ 511
Available-for-sale Securities	4,327	9,734
Total Gross Assets	1,211	694
Credit Support Agreement (CSA)	(1,013)	(423)
Total Net Asset	198	271
Total Gross Liabilities	1,083	872
Credit Support Agreement (CSA)	(945)	(605)
Total Net Liabilities	138	267
Business Combination, Contingent Consideration, Liability	1,596	335
Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Available-for-sale Securities, Equity Securities	863	511
Available-for-sale Securities	0
Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	1,179	662
Derivatives designated as hedging instruments : Liabilities	1,045	840
Available-for-sale Securities, Equity Securities	0
Available-for-sale Securities	4,327
Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Available-for-sale Securities, Equity Securities	0
Available-for-sale Securities	0
Business Combination, Contingent Consideration, Liability	1,596	335
Interest Rate Contract
Financial assets and liabilities at fair value
Derivative, Notional Amount	500	500
Derivatives designated as hedging instruments : Assets	681
Derivatives designated as hedging instruments : Liabilities	410
Derivative Assets, Noncurrent	1	6
Derivative Liabilities, Noncurrent - interest swap		3
Interest Rate Contract | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Interest Rate Contract | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	681	161
Derivatives designated as hedging instruments : Liabilities	410	292
Interest Rate Contract | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Forward foreign exchange contracts
Financial assets and liabilities at fair value
Derivative, Notional Amount	47,300	41,100
Derivatives designated as hedging instruments : Assets	498
Derivatives designated as hedging instruments : Liabilities	635
Derivatives not designated as hedging instruments : Assets	32
Derivatives not designated as hedging instruments : Liabilities	38
Forward foreign exchange contracts | Quoted prices in active markets for identical assets and liabilities Level 1
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Derivatives not designated as hedging instruments : Assets	0
Derivatives not designated as hedging instruments : Liabilities	0
Forward foreign exchange contracts | Significant other observable inputs Level 2
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	498	501
Derivatives designated as hedging instruments : Liabilities	635	548
Derivatives not designated as hedging instruments : Assets	32	32
Derivatives not designated as hedging instruments : Liabilities	38	32
Forward foreign exchange contracts | Significant unobservable inputs Level 3
Financial assets and liabilities at fair value
Derivatives designated as hedging instruments : Assets	0
Derivatives designated as hedging instruments : Liabilities	0
Derivatives not designated as hedging instruments : Assets	0
Derivatives not designated as hedging instruments : Liabilities	0
Cross currency interest rate swaps
Financial assets and liabilities at fair value
Derivative, Notional Amount	18,800	7,300
Equity Securities
Financial assets and liabilities at fair value
Available-for-sale Securities, Equity Securities	$ 863	$ 511

Fair Value Measurements - Cash,

Fair Value Measurements - Cash, Cash Equivalents and Marketable Securities (Details) - USD ($) $ in Millions	Sep. 29, 2019	Dec. 30, 2018
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Estimated Fair Value	$ 4,327	$ 9,734
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	16,249	18,107
Marketable securities	1,696	$ 1,580
Cash, Cash Equivalents, and Short-term Investments	17,944
Cash, Cash Equivalents, and Short-term Investments, Accumulated Gross Unrealized Gain	1
Cash, Cash Equivalents, And Short-Term Investments, Estimated Fair Value	17,945
Held-to-maturity Securities
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	13,618
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain	0
Held-to-maturity Securities - Estimated Fair Value	13,618
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	13,040
Marketable securities	578
Held-to-maturity Securities | Cash
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	2,667
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain	0
Held-to-maturity Securities - Estimated Fair Value	2,667
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	2,667
Held-to-maturity Securities | Other sovereign securities(1)
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	709
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain	0
Held-to-maturity Securities - Estimated Fair Value	709
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	619
Marketable securities	90
Held-to-maturity Securities | U.S. reverse repurchase agreements
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	6,182
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain	0
Held-to-maturity Securities - Estimated Fair Value	6,182
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	6,182
Marketable securities
Held-to-maturity Securities | Other reverse repurchase agreements
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	241
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain	0
Held-to-maturity Securities - Estimated Fair Value	241
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	241
Held-to-maturity Securities | Corporate debt securities(1)
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	1,647
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain	0
Held-to-maturity Securities - Estimated Fair Value	1,647
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	1,159
Marketable securities	488
Held-to-maturity Securities | Money market funds
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	1,481
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain	0
Held-to-maturity Securities - Estimated Fair Value	1,481
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	1,481
Held-to-maturity Securities | Time deposits(1)
Debt Securities, Held-to-maturity [Abstract]
Held-to-maturity Securities - Carrying Amount	691
Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain	0
Held-to-maturity Securities - Estimated Fair Value	691
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	691
Available-for-sale Securities
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	4,326
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	1
Available-for-sale Securities - Estimated Fair Value	4,327
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	3,209
Marketable securities	1,118
Available-for-sale Securities | Other sovereign securities(1)
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	4
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	0
Available-for-sale Securities - Estimated Fair Value	4
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	0
Marketable securities	4
Available-for-sale Securities | Corporate debt securities(1)
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	272
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	0
Available-for-sale Securities - Estimated Fair Value	272
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	14
Marketable securities	258
Available-for-sale Securities | US Treasury and Government [Member]
Debt Securities, Available-for-sale [Abstract]
Available-for-sale Securities - Carrying Amount	4,050
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	1
Available-for-sale Securities - Estimated Fair Value	4,051
Debt Securities, Available-for-sale and Held-to-maturity [Abstract]
Cash and Cash Equivalents	3,195
Marketable securities	$ 856

Fair Value Measurements - Sch_4

Fair Value Measurements - Schedule of Available for Sale Securities Maturities (Details) $ in Millions	Sep. 29, 2019USD ($)
Cost Basis
Due within one year	$ 4,267
Due after one year through five years	59
Due after five years through ten years	0
Total debt securities	4,326
Fair Value
Due within one year	4,268
Due after one year through five years	59
Due after five years through ten years	0
Total debt securities	$ 4,327

Fair Value Measurements - Fin_2

Fair Value Measurements - Financial Liabilities not Measured at Fair Value (Details) - USD ($) $ in Millions	Sep. 29, 2019	Dec. 30, 2018
Financial Liabilities
Current Debt	$ 2,299	$ 2,796
Non-Current Debt
Non-Current Debt	26,919	$ 27,684
Carrying Amount
Financial Liabilities
Current Debt	2,299
Non-Current Debt
Non-Current Debt	26,919
Estimated Fair Value
Financial Liabilities
Current Debt	2,349
Non-Current Debt
Non-Current Debt	$ 30,057
1.950% Notes due 2020
Non-Current Debt
Stated interest rate (as a percent)	1.95%
1.950% Notes due 2020 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 500
1.950% Notes due 2020 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 501
3.55% Notes due 2021
Non-Current Debt
Stated interest rate (as a percent)	3.55%
3.55% Notes due 2021 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 449
3.55% Notes due 2021 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 461
2.45% Notes due 2021
Non-Current Debt
Stated interest rate (as a percent)	2.45%
2.45% Notes due 2021 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 349
2.45% Notes due 2021 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 354
1.65% Notes due 2021
Non-Current Debt
Stated interest rate (as a percent)	1.65%
1.65% Notes due 2021 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 999
1.65% Notes due 2021 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 997
0.250% Notes due 2022 (1B Euro 1.0958)
Non-Current Debt
Stated interest rate (as a percent)	0.25%
0.250% Notes due 2022 (1B Euro 1.0958) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,094
0.250% Notes due 2022 (1B Euro 1.0958) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,108
2.25% Notes due 2022
Non-Current Debt
Stated interest rate (as a percent)	2.25%
2.25% Notes due 2022 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 997
2.25% Notes due 2022 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,011
6.73% Debentures due 2023
Non-Current Debt
Stated interest rate (as a percent)	6.73%
6.73% Debentures due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 250
6.73% Debentures due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 298
3.375% Notes due 2023
Non-Current Debt
Stated interest rate (as a percent)	3.375%
3.375% Notes due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 804
3.375% Notes due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 854
2.05% Notes due 2023
Non-Current Debt
Stated interest rate (as a percent)	2.05%
2.05% Notes due 2023 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 498
2.05% Notes due 2023 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 502
0.650% Notes due 2024 (750MM Euro 1.0958)
Non-Current Debt
Stated interest rate (as a percent)	0.65%
0.650% Notes due 2024 (750MM Euro 1.0958) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 819
0.650% Notes due 2024 (750MM Euro 1.0958) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 850
5.50% Notes due 2024 (500 MM GBP 1.2353)
Non-Current Debt
Stated interest rate (as a percent)	5.50%
5.50% Notes due 2024 (500 MM GBP 1.2353) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 613
5.50% Notes due 2024 (500 MM GBP 1.2353) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 752
2.625% Notes due 2025
Non-Current Debt
Stated interest rate (as a percent)	2.625%
2.625% Notes due 2025 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 748
2.625% Notes due 2025 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 771
2.45% Notes due 2026
Non-Current Debt
Stated interest rate (as a percent)	2.45%
2.45% Notes due 2026 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,992
2.45% Notes due 2026 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 2,028
2.95% Notes due 2027
Non-Current Debt
Stated interest rate (as a percent)	2.95%
2.95% Notes due 2027 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 996
2.95% Notes due 2027 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,052
2.90% Notes due 2028
Non-Current Debt
Stated interest rate (as a percent)	2.90%
2.90% Notes due 2028 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,494
2.90% Notes due 2028 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,573
1.150% Notes due 2028 (750MM Euro 1.0958)
Non-Current Debt
Stated interest rate (as a percent)	1.15%
1.150% Notes due 2028 (750MM Euro 1.0958) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 815
1.150% Notes due 2028 (750MM Euro 1.0958) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 887
6.95% Notes due 2029
Non-Current Debt
Stated interest rate (as a percent)	6.95%
6.95% Notes due 2029 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 297
6.95% Notes due 2029 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 416
4.95% Debentures due 2033
Non-Current Debt
Stated interest rate (as a percent)	4.95%
4.95% Debentures due 2033 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 498
4.95% Debentures due 2033 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 627
4.375% Notes due 2033
Non-Current Debt
Stated interest rate (as a percent)	4.375%
4.375% Notes due 2033 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 855
4.375% Notes due 2033 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,021
1.650% Notes due 2035 (1.5B Euro 1.0958)
Non-Current Debt
Stated interest rate (as a percent)	1.65%
1.650% Notes due 2035 (1.5B Euro 1.0958) | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,628
1.650% Notes due 2035 (1.5B Euro 1.0958) | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,916
3.55% Notes due 2036
Non-Current Debt
Stated interest rate (as a percent)	3.55%
3.55% Notes due 2036 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 989
3.55% Notes due 2036 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,082
5.95% Notes due 2037
Non-Current Debt
Stated interest rate (as a percent)	5.95%
5.95% Notes due 2037 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 992
5.95% Notes due 2037 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,394
3.625% Notes due 2037
Non-Current Debt
Stated interest rate (as a percent)	3.625%
3.625% Notes due 2037 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,487
3.625% Notes due 2037 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,656
3.40% Notes due 2038
Non-Current Debt
Stated interest rate (as a percent)	3.40%
3.40% Notes due 2038 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 991
3.40% Notes due 2038 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,073
5.85% Debentures due 2038
Non-Current Debt
Stated interest rate (as a percent)	5.85%
5.85% Debentures due 2038 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 696
5.85% Debentures due 2038 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 983
4.50% Debentures due 2040
Non-Current Debt
Stated interest rate (as a percent)	4.50%
4.50% Debentures due 2040 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 539
4.50% Debentures due 2040 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 668
4.85% Notes due 2041
Non-Current Debt
Stated interest rate (as a percent)	4.85%
4.85% Notes due 2041 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 297
4.85% Notes due 2041 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 387
4.50% Notes due 2043
Non-Current Debt
Stated interest rate (as a percent)	4.50%
4.50% Notes due 2043 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 495
4.50% Notes due 2043 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 629
3.70% Notes due 2046
Non-Current Debt
Stated interest rate (as a percent)	3.70%
3.70% Notes due 2046 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 1,973
3.70% Notes due 2046 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 2,232
3.75% Notes due 2047
Non-Current Debt
Stated interest rate (as a percent)	3.75%
3.75% Notes due 2047 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 991
3.75% Notes due 2047 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 1,124
3.50% Notes due 2048
Non-Current Debt
Stated interest rate (as a percent)	3.50%
3.50% Notes due 2048 | Carrying Amount
Non-Current Debt
Non-Current Debt	$ 742
3.50% Notes due 2048 | Estimated Fair Value
Non-Current Debt
Non-Current Debt	817
Other | Carrying Amount
Non-Current Debt
Non-Current Debt	32
Other | Estimated Fair Value
Non-Current Debt
Non-Current Debt	$ 33

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 29, 2019	Sep. 29, 2019	Sep. 30, 2018
Income Tax (Textuals)
Worldwide effective income tax rate (as a percent)		15.30%	17.60%
Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent	3.00%
Effective Income Tax Rate Reconciliation, Tax Settlement, Percent	2.00%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	23.00%
Unrecognized tax benefits	$ 3,600	$ 3,600
Unrecognized Tax Benefits, Increase	200
Income tax benefit, TRAF	400
TRAF tax expense related to remeasurement of deferred taxes	360
Deferred tax asset related to TRAF	1,200
Deferred tax expense related to TRAF	$ 450

Pensions and Other Benefit Pl_3

Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Retirement Plans
Components of net periodic benefit cost
Service cost	$ 275	$ 307	$ 828	$ 925
Interest cost	273	247	822	748
Expected return on plan assets	(578)	(550)	(1,742)	(1,664)
Amortization of prior service cost/(credit)	1	1	3	2
Recognized actuarial losses	145	213	435	641
Curtailments and settlements	(4)	0	3	(2)
Net periodic benefit cost	112	218	349	650
Other Benefit Plans
Components of net periodic benefit cost
Service cost	68	67	205	202
Interest cost	46	37	138	112
Expected return on plan assets	(2)	(1)	(5)	(5)
Amortization of prior service cost/(credit)	(7)	(7)	(23)	(23)
Recognized actuarial losses	32	31	97	92
Curtailments and settlements	0	0	0	0
Net periodic benefit cost	$ 137	$ 127	$ 412	$ 378

Pensions and Other Benefit Pl_4

Pensions and Other Benefit Plans (Details) $ in Millions	9 Months Ended
	Sep. 29, 2019USD ($)
U.S.
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	$ 62
International retirement plans
Defined Benefit Plan Disclosure [Line Items]
Contribution to pension plans	$ 95

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	$ 60,785	$ 62,889	$ 59,752	$ 60,160
Net change	(564)	130	(311)	(1,216)
Ending Balance	58,210	64,626	58,210	64,626
Accumulated Foreign Currency Adjustment Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance			(8,869)
Net change			(575)
Ending Balance	(9,444)		(9,444)
Accumulated Net Investment Gain (Loss) Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance			0
Net change			1
Ending Balance	1		1
Accumulated Defined Benefit Plans Adjustment Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance			(6,158)
Net change			442
Ending Balance	(5,716)		(5,716)
Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance			(195)
Net change			(179)
Ending Balance	(374)		(374)
AOCI Attributable to Parent
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Beginning Balance	(14,969)	(14,777)	(15,222)	(13,199)
Net change	(564)	130	(311)	(1,216)
Ending Balance	$ (15,533)	$ (14,647)	$ (15,533)	$ (14,647)

Earnings Per Share (Details)

Earnings Per Share (Details) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Reconciliation of basic net earnings per share to diluted net earnings per share
Basic net earnings per share	$ 0.67	$ 1.47	$ 4.19	$ 4.57
Average shares outstanding — basic	2,635,200,000	2,683,200,000	2,649,500,000	2,682,600,000
Potential shares exercisable under stock option plans	117,800,000	140,300,000	137,600,000	140,900,000
Less: shares which could be repurchased under treasury stock method	(83,800,000)	(96,700,000)	(99,700,000)	(94,700,000)
Convertible debt shares	700,000	800,000	700,000	800,000
Average shares outstanding — diluted	2,669,900,000	2,727,600,000	2,688,100,000	2,729,600,000
Diluted net earnings per share	$ 0.66	$ 1.44	$ 4.13	$ 4.49
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	19,000,000	0		0

Segments of Business and Geog_3

Segments of Business and Geographic Areas - Sales By Segment Of Business (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Sales by segment of business
Sales to customers	$ 20,729	$ 20,348	$ 61,312	$ 61,187
Percent Change (as a percent)	1.90%		0.20%
U.S.
Sales by segment of business
Sales to customers	$ 10,791	10,664	$ 31,323	31,255
Percent Change (as a percent)	1.20%		0.20%
International
Sales by segment of business
Sales to customers	$ 9,938	9,684	$ 29,989	29,932
Percent Change (as a percent)	2.60%		0.20%
CONSUMER
Sales by segment of business
Sales to customers	$ 3,469	3,415	$ 10,331	10,317
Percent Change (as a percent)	1.60%		0.10%
CONSUMER | U.S.
Sales by segment of business
Sales to customers	$ 1,394	1,370	$ 4,369	4,282
Percent Change (as a percent)	1.70%		2.00%
CONSUMER | International
Sales by segment of business
Sales to customers	$ 2,075	2,045	$ 5,962	6,035
Percent Change (as a percent)	1.40%		(1.20%)
CONSUMER | Baby Care
Sales by segment of business
Sales to customers	$ 417	472	$ 1,254	1,385
Percent Change (as a percent)	(11.60%)		(9.50%)
CONSUMER | Baby Care | U.S.
Sales by segment of business
Sales to customers	$ 91	120	$ 277	306
Percent Change (as a percent)	(24.10%)		(9.50%)
CONSUMER | Baby Care | International
Sales by segment of business
Sales to customers	$ 326	352	$ 977	1,079
Percent Change (as a percent)	(7.30%)		(9.50%)
CONSUMER | Beauty
Sales by segment of business
Sales to customers	$ 1,151	1,078	$ 3,443	3,271
Percent Change (as a percent)	6.80%		5.30%
CONSUMER | Beauty | U.S.
Sales by segment of business
Sales to customers	$ 559	543	$ 1,810	1,791
Percent Change (as a percent)	2.90%		1.10%
CONSUMER | Beauty | International
Sales by segment of business
Sales to customers	$ 592	535	$ 1,633	1,480
Percent Change (as a percent)	10.80%		10.40%
CONSUMER | Oral Care
Sales by segment of business
Sales to customers	$ 379	384	$ 1,135	1,156
Percent Change (as a percent)	(1.40%)		(1.80%)
CONSUMER | Oral Care | U.S.
Sales by segment of business
Sales to customers	$ 156	158	$ 462	472
Percent Change (as a percent)	(1.10%)		(2.10%)
CONSUMER | Oral Care | International
Sales by segment of business
Sales to customers	$ 223	226	$ 673	684
Percent Change (as a percent)	(1.60%)		(1.70%)
CONSUMER | OTC
Sales by segment of business
Sales to customers	$ 1,098	1,048	$ 3,249	3,186
Percent Change (as a percent)	4.80%		2.00%
CONSUMER | OTC | U.S.
Sales by segment of business
Sales to customers	$ 477	440	$ 1,468	1,359
Percent Change (as a percent)	8.40%		8.00%
CONSUMER | OTC | International
Sales by segment of business
Sales to customers	$ 621	608	$ 1,781	1,827
Percent Change (as a percent)	2.20%		(2.50%)
CONSUMER | Women's Health
Sales by segment of business
Sales to customers	$ 255	269	$ 733	792
Percent Change (as a percent)	(5.30%)		(7.40%)
CONSUMER | Women's Health | U.S.
Sales by segment of business
Sales to customers	$ 3	3	$ 9	10
Percent Change (as a percent)	(4.00%)		(3.80%)
CONSUMER | Women's Health | International
Sales by segment of business
Sales to customers	$ 252	266	$ 724	782
Percent Change (as a percent)	(5.40%)		(7.50%)
CONSUMER | Wound Care/Other
Sales by segment of business
Sales to customers	$ 168	164	$ 516	527
Percent Change (as a percent)	2.40%		(2.00%)
CONSUMER | Wound Care/Other | U.S.
Sales by segment of business
Sales to customers	$ 109	106	$ 343	344
Percent Change (as a percent)	1.90%		(0.40%)
CONSUMER | Wound Care/Other | International
Sales by segment of business
Sales to customers	$ 59	58	$ 173	183
Percent Change (as a percent)	3.30%		(5.00%)
PHARMACEUTICAL
Sales by segment of business
Sales to customers	$ 10,877	10,346	$ 31,650	30,544
Percent Change (as a percent)	5.10%		3.60%
PHARMACEUTICAL | U.S.
Sales by segment of business
Sales to customers	$ 6,340	6,097	$ 17,705	17,350
Percent Change (as a percent)	4.00%		2.00%
PHARMACEUTICAL | International
Sales by segment of business
Sales to customers	$ 4,537	4,249	$ 13,945	13,194
Percent Change (as a percent)	6.80%		5.70%
PHARMACEUTICAL | Immunology
Sales by segment of business
Sales to customers	$ 3,711	3,398	$ 10,428	9,778
Percent Change (as a percent)	9.30%		6.70%
PHARMACEUTICAL | Immunology | U.S.
Sales by segment of business
Sales to customers	$ 2,582	2,400	$ 7,124	6,717
Percent Change (as a percent)	7.60%		6.10%
PHARMACEUTICAL | Immunology | International
Sales by segment of business
Sales to customers	$ 1,129	998	$ 3,304	3,061
Percent Change (as a percent)	13.20%		8.00%
PHARMACEUTICAL | Immunology | REMICADE®
Sales by segment of business
Sales to customers	$ 1,136	1,379	$ 3,345	4,088
Percent Change (as a percent)	(17.60%)		(18.20%)
PHARMACEUTICAL | Immunology | REMICADE® | U.S.
Sales by segment of business
Sales to customers	$ 749	987	$ 2,324	2,821
Percent Change (as a percent)	(24.10%)		(17.60%)
PHARMACEUTICAL | Immunology | REMICADE® | U.S. Exports
Sales by segment of business
Sales to customers	$ 88	100	$ 226	346
Percent Change (as a percent)	(12.00%)		(34.70%)
PHARMACEUTICAL | Immunology | REMICADE® | International
Sales by segment of business
Sales to customers	$ 299	292	$ 795	921
Percent Change (as a percent)	2.50%		(13.70%)
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA®
Sales by segment of business
Sales to customers	$ 586	536	$ 1,673	1,602
Percent Change (as a percent)	9.60%		4.50%
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | U.S.
Sales by segment of business
Sales to customers	$ 313	281	$ 857	779
Percent Change (as a percent)	11.60%		10.00%
PHARMACEUTICAL | Immunology | SIMPONI / SIMPONI ARIA® | International
Sales by segment of business
Sales to customers	$ 273	255	$ 816	823
Percent Change (as a percent)	7.30%		(0.80%)
PHARMACEUTICAL | Immunology | STELARA®
Sales by segment of business
Sales to customers	$ 1,698	1,310	$ 4,661	3,712
Percent Change (as a percent)	29.60%		25.60%
PHARMACEUTICAL | Immunology | STELARA® | U.S.
Sales by segment of business
Sales to customers	$ 1,212	889	$ 3,152	2,460
Percent Change (as a percent)	36.30%		28.10%
PHARMACEUTICAL | Immunology | STELARA® | International
Sales by segment of business
Sales to customers	$ 487	421	$ 1,509	1,252
Percent Change (as a percent)	15.70%		20.50%
PHARMACEUTICAL | Immunology | TREMFYA®
Sales by segment of business
Sales to customers	$ 290	171	$ 742	369
Percent Change (as a percent)	69.00%
PHARMACEUTICAL | Immunology | TREMFYA® | U.S.
Sales by segment of business
Sales to customers	$ 221	143	$ 565	311
Percent Change (as a percent)	54.30%		81.70%
PHARMACEUTICAL | Immunology | TREMFYA® | International
Sales by segment of business
Sales to customers	$ 69	28	$ 177	58
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY
Sales by segment of business
Sales to customers	$ 2	2	$ 8	7
Percent Change (as a percent)	(4.40%)		13.70%
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | U.S.
Sales by segment of business
Sales to customers	$ 0	0	$ 0	0
Percent Change (as a percent)	0.00%		0.00%
PHARMACEUTICAL | Immunology | OTHER IMMUNOLOGY | International
Sales by segment of business
Sales to customers	$ 2	2	$ 8	7
Percent Change (as a percent)	(4.40%)		13.70%
PHARMACEUTICAL | Infectious Diseases
Sales by segment of business
Sales to customers	$ 839	823	$ 2,547	2,502
Percent Change (as a percent)	1.90%		1.80%
PHARMACEUTICAL | Infectious Diseases | U.S.
Sales by segment of business
Sales to customers	$ 418	345	$ 1,162	1,006
Percent Change (as a percent)	21.20%		15.50%
PHARMACEUTICAL | Infectious Diseases | International
Sales by segment of business
Sales to customers	$ 421	478	$ 1,385	1,496
Percent Change (as a percent)	(12.00%)		(7.40%)
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine
Sales by segment of business
Sales to customers	$ 218	202	$ 639	623
Percent Change (as a percent)	7.90%		2.60%
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | U.S.
Sales by segment of business
Sales to customers	$ 12	13	$ 36	42
Percent Change (as a percent)	(7.30%)		(14.30%)
PHARMACEUTICAL | Infectious Diseases | EDURANT® / rilpivirine | International
Sales by segment of business
Sales to customers	$ 206	189	$ 603	581
Percent Change (as a percent)	9.00%		3.80%
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA®
Sales by segment of business
Sales to customers	$ 508	490	$ 1,566	1,460
Percent Change (as a percent)	3.70%		7.30%
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | U.S.
Sales by segment of business
Sales to customers	$ 373	297	$ 1,032	847
Percent Change (as a percent)	25.40%		21.80%
PHARMACEUTICAL | Infectious Diseases | PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA® | International
Sales by segment of business
Sales to customers	$ 135	193	$ 534	613
Percent Change (as a percent)	(29.80%)		(12.80%)
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES
Sales by segment of business
Sales to customers	$ 113	131	$ 342	419
Percent Change (as a percent)	(13.90%)		(18.60%)
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | U.S.
Sales by segment of business
Sales to customers	$ 33	35	$ 94	117
Percent Change (as a percent)	(4.30%)		(19.60%)
PHARMACEUTICAL | Infectious Diseases | OTHER INFECTIOUS DISEASES | International
Sales by segment of business
Sales to customers	$ 80	96	$ 248	302
Percent Change (as a percent)	(17.40%)		(18.20%)
PHARMACEUTICAL | Neuroscience
Sales by segment of business
Sales to customers	$ 1,595	1,490	$ 4,762	4,577
Percent Change (as a percent)	7.10%		4.00%
PHARMACEUTICAL | Neuroscience | U.S.
Sales by segment of business
Sales to customers	$ 785	651	$ 2,172	1,914
Percent Change (as a percent)	20.70%		13.50%
PHARMACEUTICAL | Neuroscience | International
Sales by segment of business
Sales to customers	$ 810	839	$ 2,590	2,663
Percent Change (as a percent)	(3.50%)		(2.70%)
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate
Sales by segment of business
Sales to customers	$ 193	157	$ 544	513
Percent Change (as a percent)	23.50%		6.10%
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate | U.S.
Sales by segment of business
Sales to customers	$ 84	57	$ 196	191
Percent Change (as a percent)	48.20%		2.90%
PHARMACEUTICAL | Neuroscience | CONCERTA® / methylphenidate | International
Sales by segment of business
Sales to customers	$ 109	100	$ 348	322
Percent Change (as a percent)	9.40%		8.00%
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA®
Sales by segment of business
Sales to customers	$ 851	749	$ 2,459	2,165
Percent Change (as a percent)	13.70%		13.60%
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® | U.S.
Sales by segment of business
Sales to customers	$ 554	468	$ 1,543	1,306
Percent Change (as a percent)	18.30%		18.10%
PHARMACEUTICAL | Neuroscience | INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA® | International
Sales by segment of business
Sales to customers	$ 297	281	$ 916	859
Percent Change (as a percent)	5.90%		6.70%
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA®
Sales by segment of business
Sales to customers	$ 167	175	$ 528	559
Percent Change (as a percent)	(3.80%)		(5.40%)
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | U.S.
Sales by segment of business
Sales to customers	$ 79	76	$ 237	238
Percent Change (as a percent)	4.90%		(0.50%)
PHARMACEUTICAL | Neuroscience | RISPERDAL CONSTA® | International
Sales by segment of business
Sales to customers	$ 89	99	$ 292	321
Percent Change (as a percent)	(10.50%)		(9.10%)
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE
Sales by segment of business
Sales to customers	$ 384	409	$ 1,231	1,340
Percent Change (as a percent)	(6.60%)		(8.20%)
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | U.S.
Sales by segment of business
Sales to customers	$ 68	50	$ 196	179
Percent Change (as a percent)	35.30%		9.70%
PHARMACEUTICAL | Neuroscience | OTHER NEUROSCIENCE | International
Sales by segment of business
Sales to customers	$ 316	359	$ 1,035	1,161
Percent Change (as a percent)	(12.50%)		(10.90%)
PHARMACEUTICAL | Oncology
Sales by segment of business
Sales to customers	$ 2,761	2,588	$ 7,976	7,355
Percent Change (as a percent)	6.70%		8.40%
PHARMACEUTICAL | Oncology | U.S.
Sales by segment of business
Sales to customers	$ 1,171	1,250	$ 3,146	3,268
Percent Change (as a percent)	(6.30%)		(3.70%)
PHARMACEUTICAL | Oncology | International
Sales by segment of business
Sales to customers	$ 1,590	1,338	$ 4,830	4,087
Percent Change (as a percent)	18.80%		18.20%
PHARMACEUTICAL | Oncology | DARZALEX®
Sales by segment of business
Sales to customers	$ 765	498	$ 2,168	1,441
Percent Change (as a percent)	53.50%		50.40%
PHARMACEUTICAL | Oncology | DARZALEX® | U.S.
Sales by segment of business
Sales to customers	$ 402	318	$ 1,123	880
Percent Change (as a percent)	26.10%		27.60%
PHARMACEUTICAL | Oncology | DARZALEX® | International
Sales by segment of business
Sales to customers	$ 363	180	$ 1,045	561
Percent Change (as a percent)			86.20%
PHARMACEUTICAL | Oncology | IMBRUVICA®
Sales by segment of business
Sales to customers	$ 921	705	$ 2,536	1,912
Percent Change (as a percent)	30.60%		32.60%
PHARMACEUTICAL | Oncology | IMBRUVICA® | U.S.
Sales by segment of business
Sales to customers	$ 447	334	$ 1,163	811
Percent Change (as a percent)	34.00%		43.50%
PHARMACEUTICAL | Oncology | IMBRUVICA® | International
Sales by segment of business
Sales to customers	$ 475	371	$ 1,373	1,101
Percent Change (as a percent)	27.60%		24.60%
PHARMACEUTICAL | Oncology | VELCADE®
Sales by segment of business
Sales to customers	$ 149	271	$ 636	864
Percent Change (as a percent)	(44.80%)		(26.30%)
PHARMACEUTICAL | Oncology | VELCADE® | U.S.
Sales by segment of business
Sales to customers	$ 0	0	$ 0	0
Percent Change (as a percent)	0.00%		0.00%
PHARMACEUTICAL | Oncology | VELCADE® | International
Sales by segment of business
Sales to customers	$ 149	271	$ 636	864
Percent Change (as a percent)	(44.80%)		(26.30%)
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate
Sales by segment of business
Sales to customers	$ 741	958	$ 2,118	2,712
Percent Change (as a percent)	(22.70%)		(21.90%)
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate | U.S.
Sales by segment of business
Sales to customers	$ 233	527	$ 616	1,420
Percent Change (as a percent)	(55.80%)		(56.60%)
PHARMACEUTICAL | Oncology | ZYTIGA® / abiraterone acetate | International
Sales by segment of business
Sales to customers	$ 508	431	$ 1,502	1,292
Percent Change (as a percent)	17.80%		16.20%
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY
Sales by segment of business
Sales to customers	$ 186	156	$ 519	426
Percent Change (as a percent)	18.80%		21.60%
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | U.S.
Sales by segment of business
Sales to customers	$ 91	71	$ 245	157
Percent Change (as a percent)	26.70%		54.70%
PHARMACEUTICAL | Oncology | OTHER ONCOLOGY | International
Sales by segment of business
Sales to customers	$ 95	85	$ 274	269
Percent Change (as a percent)	12.20%		2.10%
PHARMACEUTICAL | Pulmonary Hypertension
Sales by segment of business
Sales to customers	$ 654	656	$ 2,000	1,906
Percent Change (as a percent)	(0.30%)		4.90%
PHARMACEUTICAL | Pulmonary Hypertension | U.S.
Sales by segment of business
Sales to customers	$ 427	425	$ 1,296	1,215
Percent Change (as a percent)	0.50%		6.60%
PHARMACEUTICAL | Pulmonary Hypertension | International
Sales by segment of business
Sales to customers	$ 227	231	$ 704	691
Percent Change (as a percent)	(1.60%)		1.90%
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT®
Sales by segment of business
Sales to customers	$ 347	310	$ 1,001	892
Percent Change (as a percent)	11.70%		12.20%
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | U.S.
Sales by segment of business
Sales to customers	$ 206	182	$ 581	511
Percent Change (as a percent)	12.90%		13.70%
PHARMACEUTICAL | Pulmonary Hypertension | OPSUMIT® | International
Sales by segment of business
Sales to customers	$ 140	128	$ 419	381
Percent Change (as a percent)	10.10%		10.20%
PHARMACEUTICAL | Pulmonary Hypertension | TRACLEER® / bosentan
Sales by segment of business
Sales to customers	$ 65	139	$ 285	422
Percent Change (as a percent)	(52.70%)		(32.40%)
PHARMACEUTICAL | Pulmonary Hypertension | TRACLEER® / bosentan | U.S.
Sales by segment of business
Sales to customers	$ 19	69	$ 121	208
Percent Change (as a percent)	(72.40%)		(41.80%)
PHARMACEUTICAL | Pulmonary Hypertension | TRACLEER® / bosentan | International
Sales by segment of business
Sales to customers	$ 46	70	$ 164	214
Percent Change (as a percent)	(32.80%)		(23.30%)
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI®
Sales by segment of business
Sales to customers	$ 210	171	$ 611	482
Percent Change (as a percent)	23.40%		26.80%
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | U.S.
Sales by segment of business
Sales to customers	$ 185	154	$ 536	433
Percent Change (as a percent)	20.20%		23.90%
PHARMACEUTICAL | Pulmonary Hypertension | UPTRAVI® | International
Sales by segment of business
Sales to customers	$ 25	17	$ 75	49
Percent Change (as a percent)	52.10%		52.80%
PHARMACEUTICAL | Pulmonary Hypertension | OTHER
Sales by segment of business
Sales to customers	$ 31	36	$ 103	110
Percent Change (as a percent)	(12.60%)		(6.40%)
PHARMACEUTICAL | Pulmonary Hypertension | OTHER | U.S.
Sales by segment of business
Sales to customers	$ 17	20	$ 58	63
Percent Change (as a percent)	(10.10%)		(8.90%)
PHARMACEUTICAL | Pulmonary Hypertension | OTHER | International
Sales by segment of business
Sales to customers	$ 15	16	$ 46	47
Percent Change (as a percent)	(15.40%)		(3.00%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other
Sales by segment of business
Sales to customers	$ 1,316	1,391	$ 3,936	4,426
Percent Change (as a percent)	(5.40%)		(11.10%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | U.S.
Sales by segment of business
Sales to customers	$ 955	1,026	$ 2,804	3,230
Percent Change (as a percent)	(6.90%)		(13.20%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | International
Sales by segment of business
Sales to customers	$ 360	365	$ 1,131	1,196
Percent Change (as a percent)	(1.30%)		(5.40%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO®
Sales by segment of business
Sales to customers	$ 613	612	$ 1,704	1,869
Percent Change (as a percent)	0.10%		(8.90%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | U.S.
Sales by segment of business
Sales to customers	$ 613	612	$ 1,704	1,869
Percent Change (as a percent)	0.10%		(8.90%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | XARELTO® | International
Sales by segment of business
Sales to customers	$ 0	0	$ 0	0
Percent Change (as a percent)	0.00%		0.00%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET®
Sales by segment of business
Sales to customers	$ 179	190	$ 558	653
Percent Change (as a percent)	(5.80%)		(14.60%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | U.S.
Sales by segment of business
Sales to customers	$ 125	150	$ 411	523
Percent Change (as a percent)	(16.60%)		(21.30%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | INVOKANA® / INVOKAMET® | International
Sales by segment of business
Sales to customers	$ 55	40	$ 147	130
Percent Change (as a percent)	33.90%		12.30%
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX®
Sales by segment of business
Sales to customers	$ 198	255	$ 607	767
Percent Change (as a percent)	(22.40%)		(20.90%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | U.S.
Sales by segment of business
Sales to customers	$ 126	178	$ 387	523
Percent Change (as a percent)	(29.60%)		(26.10%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | PROCRIT® / EPREX® | International
Sales by segment of business
Sales to customers	$ 72	77	$ 220	244
Percent Change (as a percent)	(5.70%)		(9.80%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER
Sales by segment of business
Sales to customers	$ 325	334	$ 1,067	1,137
Percent Change (as a percent)	(2.20%)		(6.10%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER | U.S.
Sales by segment of business
Sales to customers	$ 91	86	$ 302	315
Percent Change (as a percent)	8.10%		(3.80%)
PHARMACEUTICAL | Cardiovascular / Metabolism / Other | OTHER | International
Sales by segment of business
Sales to customers	$ 234	248	$ 765	822
Percent Change (as a percent)	(5.70%)		(6.90%)
MEDICAL DEVICES
Sales by segment of business
Sales to customers	$ 6,383	6,587	$ 19,331	20,326
Percent Change (as a percent)	(3.10%)		(4.90%)
MEDICAL DEVICES | U.S.
Sales by segment of business
Sales to customers	$ 3,057	3,197	$ 9,249	9,623
Percent Change (as a percent)	(4.40%)		(3.90%)
MEDICAL DEVICES | International
Sales by segment of business
Sales to customers	$ 3,326	3,390	$ 10,082	10,703
Percent Change (as a percent)	(1.90%)		(5.80%)
MEDICAL DEVICES | Diabetes Care
Sales by segment of business
Sales to customers	$ 0	315	$ 0	1,009
MEDICAL DEVICES | Diabetes Care | U.S.
Sales by segment of business
Sales to customers	0	125	0	371
MEDICAL DEVICES | Diabetes Care | International
Sales by segment of business
Sales to customers	0	190	0	638
MEDICAL DEVICES | Interventional Solutions
Sales by segment of business
Sales to customers	$ 741	653	$ 2,223	1,960
Percent Change (as a percent)	13.40%		13.40%
MEDICAL DEVICES | Interventional Solutions | U.S.
Sales by segment of business
Sales to customers	$ 357	320	$ 1,066	947
Percent Change (as a percent)	11.50%		12.60%
MEDICAL DEVICES | Interventional Solutions | International
Sales by segment of business
Sales to customers	$ 382	333	$ 1,156	1,013
Percent Change (as a percent)	15.30%		14.20%
MEDICAL DEVICES | Orthopaedics
Sales by segment of business
Sales to customers	$ 2,138	2,111	$ 6,566	6,623
Percent Change (as a percent)	1.20%		(0.90%)
MEDICAL DEVICES | Orthopaedics | U.S.
Sales by segment of business
Sales to customers	$ 1,301	1,284	$ 3,950	3,923
Percent Change (as a percent)	1.20%		0.70%
MEDICAL DEVICES | Orthopaedics | International
Sales by segment of business
Sales to customers	$ 837	827	$ 2,616	2,700
Percent Change (as a percent)	1.20%		(3.10%)
MEDICAL DEVICES | Orthopaedics | HIPS
Sales by segment of business
Sales to customers	$ 336	330	$ 1,061	1,053
Percent Change (as a percent)	1.70%		0.70%
MEDICAL DEVICES | Orthopaedics | HIPS | U.S.
Sales by segment of business
Sales to customers	$ 204	201	$ 633	621
Percent Change (as a percent)	1.10%		1.80%
MEDICAL DEVICES | Orthopaedics | HIPS | International
Sales by segment of business
Sales to customers	$ 133	129	$ 428	432
Percent Change (as a percent)	2.70%		(0.80%)
MEDICAL DEVICES | Orthopaedics | KNEES
Sales by segment of business
Sales to customers	$ 344	341	$ 1,085	1,110
Percent Change (as a percent)	1.20%		(2.20%)
MEDICAL DEVICES | Orthopaedics | KNEES | U.S.
Sales by segment of business
Sales to customers	$ 209	215	$ 650	672
Percent Change (as a percent)	(2.70%)		(3.30%)
MEDICAL DEVICES | Orthopaedics | KNEES | International
Sales by segment of business
Sales to customers	$ 136	126	$ 435	438
Percent Change (as a percent)	7.90%		(0.60%)
MEDICAL DEVICES | Orthopaedics | TRAUMA
Sales by segment of business
Sales to customers	$ 677	654	$ 2,034	2,025
Percent Change (as a percent)	3.50%		0.40%
MEDICAL DEVICES | Orthopaedics | TRAUMA | U.S.
Sales by segment of business
Sales to customers	$ 415	395	$ 1,239	1,196
Percent Change (as a percent)	5.10%		3.60%
MEDICAL DEVICES | Orthopaedics | TRAUMA | International
Sales by segment of business
Sales to customers	$ 262	259	$ 795	829
Percent Change (as a percent)	1.00%		(4.10%)
MEDICAL DEVICES | Orthopaedics | SPINE & OTHER
Sales by segment of business
Sales to customers	$ 778	786	$ 2,384	2,435
Percent Change (as a percent)	(0.90%)		(2.10%)
MEDICAL DEVICES | Orthopaedics | SPINE & OTHER | U.S.
Sales by segment of business
Sales to customers	$ 472	473	$ 1,427	1,434
Percent Change (as a percent)	(0.20%)		(0.50%)
MEDICAL DEVICES | Orthopaedics | SPINE & OTHER | International
Sales by segment of business
Sales to customers	$ 306	313	$ 957	1,001
Percent Change (as a percent)	(2.00%)		(4.40%)
MEDICAL DEVICES | Surgery
Sales by segment of business
Sales to customers	$ 2,311	2,376	$ 7,059	7,314
Percent Change (as a percent)	(2.70%)		(3.50%)
MEDICAL DEVICES | Surgery | U.S.
Sales by segment of business
Sales to customers	$ 940	1,016	$ 2,867	3,031
Percent Change (as a percent)	(7.40%)		(5.40%)
MEDICAL DEVICES | Surgery | International
Sales by segment of business
Sales to customers	$ 1,371	1,360	$ 4,192	4,283
Percent Change (as a percent)	0.80%		(2.10%)
MEDICAL DEVICES | Surgery | ADVANCED
Sales by segment of business
Sales to customers	$ 1,010	976	$ 3,019	2,947
Percent Change (as a percent)	3.60%		2.40%
MEDICAL DEVICES | Surgery | ADVANCED | U.S.
Sales by segment of business
Sales to customers	$ 409	421	$ 1,209	1,216
Percent Change (as a percent)	(2.80%)		(0.60%)
MEDICAL DEVICES | Surgery | ADVANCED | International
Sales by segment of business
Sales to customers	$ 602	555	$ 1,811	1,731
Percent Change (as a percent)	8.30%		4.60%
MEDICAL DEVICES | Surgery | GENERAL
Sales by segment of business
Sales to customers	$ 1,101	1,080	$ 3,309	3,376
Percent Change (as a percent)	1.90%		(2.00%)
MEDICAL DEVICES | Surgery | GENERAL | U.S.
Sales by segment of business
Sales to customers	$ 443	423	$ 1,311	1,282
Percent Change (as a percent)	4.70%		2.30%
MEDICAL DEVICES | Surgery | GENERAL | International
Sales by segment of business
Sales to customers	$ 659	657	$ 1,998	2,094
Percent Change (as a percent)	0.20%		(4.60%)
MEDICAL DEVICES | Surgery | SPECIALTY
Sales by segment of business
Sales to customers	$ 200	320	$ 731	991
Percent Change (as a percent)	(37.40%)		(26.20%)
MEDICAL DEVICES | Surgery | SPECIALTY | U.S.
Sales by segment of business
Sales to customers	$ 88	172	$ 347	533
Percent Change (as a percent)	(48.00%)		(34.90%)
MEDICAL DEVICES | Surgery | SPECIALTY | International
Sales by segment of business
Sales to customers	$ 110	148	$ 383	458
Percent Change (as a percent)	(25.00%)		(16.20%)
MEDICAL DEVICES | Vision
Sales by segment of business
Sales to customers	$ 1,193	1,132	$ 3,483	3,420
Percent Change (as a percent)	5.40%		1.80%
MEDICAL DEVICES | Vision | U.S.
Sales by segment of business
Sales to customers	$ 459	452	$ 1,366	1,351
Percent Change (as a percent)	1.40%		1.10%
MEDICAL DEVICES | Vision | International
Sales by segment of business
Sales to customers	$ 734	680	$ 2,117	2,069
Percent Change (as a percent)	8.00%		2.30%
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER
Sales by segment of business
Sales to customers	$ 893	835	$ 2,559	2,486
Percent Change (as a percent)	7.00%		2.90%
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | U.S.
Sales by segment of business
Sales to customers	$ 339	319	$ 993	948
Percent Change (as a percent)	6.20%		4.70%
MEDICAL DEVICES | Vision | CONTACT LENSES / OTHER | International
Sales by segment of business
Sales to customers	$ 555	516	$ 1,566	1,538
Percent Change (as a percent)	7.40%		1.80%
MEDICAL DEVICES | Vision | SURGICAL
Sales by segment of business
Sales to customers	$ 299	297	$ 923	934
Percent Change (as a percent)	0.90%		(1.10%)
MEDICAL DEVICES | Vision | SURGICAL | U.S.
Sales by segment of business
Sales to customers	$ 120	133	$ 373	403
Percent Change (as a percent)	(10.00%)		(7.40%)
MEDICAL DEVICES | Vision | SURGICAL | International
Sales by segment of business
Sales to customers	$ 180	$ 164	$ 551	$ 531
Percent Change (as a percent)	9.90%		3.70%

Segments of Business and Geog_4

Segments of Business and Geographic Areas - Operating Profit by Segment of Business (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Segment Reporting Information [Line Items]
Percentage Change In Sales By Geographic Area	1.90%		0.20%
Sales to customers	$ 20,729	$ 20,348	$ 61,312	$ 61,187
Percentage Change in Operating Income Loss	(62.80%)		(11.90%)
Earnings before provision for taxes on income	$ 1,647	4,423	$ 13,110	14,877
In-process research and development	0	1,126	890	1,126
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability			(129)	162
Restructuring charges	69	88	162	187
CONSUMER
Segment Reporting Information [Line Items]
Sales to customers	3,469	3,415	10,331	10,317
Restructuring charges			100
Litigation expense			200
PHARMACEUTICAL
Segment Reporting Information [Line Items]
Sales to customers	10,877	10,346	31,650	30,544
In-process research and development		1,100	900	1,100
Restructuring charges			100
Litigation expense	4,000		4,300
Research and Development Expense			300
Medical Devices
Segment Reporting Information [Line Items]
Sales to customers	6,383	6,587	19,331	20,326
Restructuring charges	100	200	200	400
Litigation expense			300	700
Operating Segments
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 1,823	4,653	$ 13,664	15,722
Percentage Change in Operating Income Loss	(60.80%)		(13.10%)
Operating Segments | CONSUMER
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 653	510	$ 1,800	1,887
Percentage Change in Operating Income Loss	28.00%		(4.60%)
Amortization	$ 100	100	$ 300	200
Gain (Loss) on Disposition of Assets				300
Operating Segments | PHARMACEUTICAL
Segment Reporting Information [Line Items]
Total Segment Operating Income	(222)	2,876	$ 5,786	10,193
Percentage Change in Operating Income Loss			(43.20%)
Amortization	800	700	$ 2,400	2,300
Gain (Loss) on Disposition of Assets				100
Unrealized Gain (Loss) on Securities	(100)		200
Operating Segments | Medical Devices
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 1,392	1,267	$ 6,078	3,642
Percentage Change in Operating Income Loss	9.90%		66.90%
Amortization	$ 200	300	$ 700	800
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Total Segment Operating Income	$ 176	230	554	845
Ci:z Holdings Co. Ltd. | CONSUMER
Segment Reporting Information [Line Items]
Gain on sale of equity investments			300
Actelion | PHARMACEUTICAL
Segment Reporting Information [Line Items]
Acquisition related costs			$ 100	200
XO1 [Member] | PHARMACEUTICAL
Segment Reporting Information [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability		200		(200)
United States
Segment Reporting Information [Line Items]
Percentage Change In Sales By Geographic Area	1.20%		0.20%
Sales to customers	$ 10,791	10,664	$ 31,323	31,255
United States | CONSUMER
Segment Reporting Information [Line Items]
Sales to customers	1,394	1,370	4,369	4,282
United States | PHARMACEUTICAL
Segment Reporting Information [Line Items]
Sales to customers	6,340	6,097	17,705	17,350
United States | Medical Devices
Segment Reporting Information [Line Items]
Sales to customers	$ 3,057	3,197	$ 9,249	9,623
Europe
Segment Reporting Information [Line Items]
Percentage Change In Sales By Geographic Area	1.00%		(1.60%)
Sales to customers	$ 4,461	4,416	$ 13,803	14,023
Western Hemisphere, excluding U.S.
Segment Reporting Information [Line Items]
Percentage Change In Sales By Geographic Area	(4.00%)		(4.50%)
Sales to customers	$ 1,488	1,550	$ 4,446	4,657
Asia-Pacific, Africa
Segment Reporting Information [Line Items]
Percentage Change In Sales By Geographic Area	7.30%		4.30%
Sales to customers	$ 3,989	$ 3,718	$ 11,740	$ 11,252
ADVANCED | Operating Segments | Medical Devices
Segment Reporting Information [Line Items]
Gain (Loss) on Disposition of Business			$ 2,000

Segments of Business and Geog_5

Segments of Business and Geographic Areas - Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Sales by geographic area
Sales	$ 20,729	$ 20,348	$ 61,312	$ 61,187
Percentage Change In Sales By Geographic Area	1.90%		0.20%
United States
Sales by geographic area
Sales	$ 10,791	10,664	$ 31,323	31,255
Percentage Change In Sales By Geographic Area	1.20%		0.20%
Europe
Sales by geographic area
Sales	$ 4,461	4,416	$ 13,803	14,023
Percentage Change In Sales By Geographic Area	1.00%		(1.60%)
Western Hemisphere, excluding U.S.
Sales by geographic area
Sales	$ 1,488	1,550	$ 4,446	4,657
Percentage Change In Sales By Geographic Area	(4.00%)		(4.50%)
Asia-Pacific, Africa
Sales by geographic area
Sales	$ 3,989	$ 3,718	$ 11,740	$ 11,252
Percentage Change In Sales By Geographic Area	7.30%		4.30%

Business Combinations and Div_2

Business Combinations and Divestitures - Narrative (Details) ¥ / shares in Units, $ in Millions, ¥ in Billions	Oct. 23, 2018USD ($)	Oct. 23, 2018JPY (¥)	Sep. 29, 2019USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 29, 2019USD ($)	Sep. 30, 2018USD ($)	Apr. 01, 2019USD ($)	Jan. 17, 2019¥ / shares	Jan. 16, 2019	Dec. 30, 2018USD ($)	Oct. 22, 2018
Business Acquisition [Line Items]
Payments to acquire businesses							$ 5,562	$ 897
Contingent consideration			$ 1,596				1,596					$ 335
Goodwill			33,291				33,291					30,453
Other (income) expense, net			(4,214)			$ (3)	$ (2,509)	$ (427)
Weighted average useful life							15 years 3 months 18 days
Auris Health
Business Acquisition [Line Items]
Payments to acquire businesses				$ 3,400
Contingent consideration									$ 2,350
Intangible assets									3,000
Goodwill									2,000
Marketable securities									200
Current liabilities									1,800
Noncurrent liability, contingent consideration									$ 1,100
Discount rate									10.00%
Ci:z Holdings Co. Ltd.
Business Acquisition [Line Items]
Intangible assets			1,500				$ 1,500
Goodwill			1,200				1,200
Current liabilities			400				400
Business acquisition cost	$ 2,100	¥ 230
Foreign exchange rate											109.06
Share price (in dollars per share) | ¥ / shares										¥ 5,900
Percentage of voting interests acquired													20.00%
Other (income) expense, net					$ 300
Adjustments made to intangible assets			100				100
AdvancedSterilizationProducts
Business Acquisition [Line Items]
Gain (loss) on disposition of business			2,000
Discontinued Operations, Held-for-sale or Disposed of by Sale | AdvancedSterilizationProducts
Business Acquisition [Line Items]
Disposal group consideration									$ 2,800
Disposal group consideration, cash									2,700
Receivables retained									$ 100
Assets held for sale, current												200
Discontinued Operations, Held-for-sale or Disposed of by Sale | Supply Chain
Business Acquisition [Line Items]
Assets held for sale, current			$ 200				$ 200					$ 300
Minimum | Auris Health
Business Acquisition [Line Items]
Probability of success factor									55.00%
Maximum | Auris Health
Business Acquisition [Line Items]
Probability of success factor									95.00%

Legal Proceedings (Details)

Legal Proceedings (Details) $ in Millions	1 Months Ended	9 Months Ended
	Oct. 31, 2019USD ($)	Sep. 29, 2019USD ($)patientclaimant
ASR
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants		1,400
Pinnacle Acetabular Cup System
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants		10,500
Pelvic Meshes
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants		19,800
Risperdal
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants		13,600
XARELTO®
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants		30,700
Talc
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants		16,800
Invokana
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants		700
Physiomesh [Member]
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants		3,100
Opiods
Legal Proceeding (Textuals)
Product Liability Contingency Number Of Claimants		2,500
DePuy ASR U.S. | settled litigation
Legal Proceeding (Textuals)
Number of patients in settlement | patient		10,000
Oklahoma Attorney General vs. Johnson & Johnson and JPI | Judicial Ruling
Legal Proceeding (Textuals)
Loss Contingency, Damages Awarded, Value | $		$ 572
Damages from Product Defects | Baby Powder | Judicial Ruling
Legal Proceeding (Textuals)
Litigation contingency | $		$ 4,700
Subsequent Event | Judicial Ruling
Legal Proceeding (Textuals)
Loss Contingency, Damages Awarded, Value | $	$ 8,000
Subsequent Event | Pending Litigation
Legal Proceeding (Textuals)
Loss Contingency, Estimate of Possible Loss | $	$ 4,000

Restructuring - Narrative (Deta

Restructuring - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 69	$ 88	$ 162	$ 187
Supply Chain
Restructuring Cost and Reserve [Line Items]
Restructuring charges	128		360
Restructuring charges recorded to date	598		598
Supply Chain | Cost of products sold
Restructuring Cost and Reserve [Line Items]
Restructuring charges	20		81
Supply Chain | Other (income) expense
Restructuring Cost and Reserve [Line Items]
Restructuring charges	39		117
Supply Chain | Minimum
Restructuring Cost and Reserve [Line Items]
Restructuring estimated cost	1,900		1,900
Cost savings expected	600		600
Supply Chain | Maximum
Restructuring Cost and Reserve [Line Items]
Restructuring estimated cost	2,300		2,300
Cost savings expected	800		800
Medical Devices
Restructuring Cost and Reserve [Line Items]
Restructuring charges			360
Medical Devices
Restructuring Cost and Reserve [Line Items]
Restructuring charges	$ 100	$ 200	$ 200	$ 400
Medical Devices | Supply Chain | Minimum
Restructuring Cost and Reserve [Line Items]
Period for activity			4 years
Medical Devices | Supply Chain | Maximum
Restructuring Cost and Reserve [Line Items]
Period for activity			5 years

Restructuring - Schedule of Res

Restructuring - Schedule of Restructuring Reserve (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 29, 2019	Sep. 30, 2018	Sep. 29, 2019	Sep. 30, 2018
Restructuring Reserve [Roll Forward]
Restructuring charges	$ 69	$ 88	$ 162	$ 187
Period of cash outlays for severance expected to be paid out			2 years
Medical Devices
Restructuring Reserve [Roll Forward]
Reserve balance beginning			$ 242
Restructuring charges			360
Payments for Restructuring			(316)
Restructuring Reserve, Settled without Cash			(81)
Reserve balance ending	205		205
Medical Devices | Employee Severance
Restructuring Reserve [Roll Forward]
Reserve balance beginning			194
Restructuring charges			0
Payments for Restructuring			(14)
Restructuring Reserve, Settled without Cash			0
Reserve balance ending	180		180
Medical Devices | Asset Write-off
Restructuring Reserve [Roll Forward]
Reserve balance beginning			0
Restructuring charges			81
Payments for Restructuring			0
Restructuring Reserve, Settled without Cash			(81)
Reserve balance ending	0		0
Medical Devices | Other Restructuring
Restructuring Reserve [Roll Forward]
Reserve balance beginning			48
Restructuring charges			279
Payments for Restructuring			(302)
Restructuring Reserve, Settled without Cash			0
Reserve balance ending	$ 25		$ 25